Genetic defects in the selective or non-selective transport functions of the KIDNEY TUBULES.
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
A group of inherited kidney disorders characterized by the abnormally elevated levels of AMINO ACIDS in URINE. Genetic mutations of transport proteins result in the defective reabsorption of free amino acids at the PROXIMAL RENAL TUBULES. Renal aminoaciduria are classified by the specific amino acid or acids involved.
Long convoluted tubules in the nephrons. They collect filtrate from blood passing through the KIDNEY GLOMERULUS and process this filtrate into URINE. Each renal tubule consists of a BOWMAN CAPSULE; PROXIMAL KIDNEY TUBULE; LOOP OF HENLE; DISTAL KIDNEY TUBULE; and KIDNEY COLLECTING DUCT leading to the central cavity of the kidney (KIDNEY PELVIS) that connects to the URETER.
Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.
A group of glycine amides of aminobenzoic acids.
Disorders affecting amino acid metabolism. The majority of these disorders are inherited and present in the neonatal period with metabolic disturbances (e.g., ACIDOSIS) and neurologic manifestations. They are present at birth, although they may not become symptomatic until later in life.
The renal tubule portion that extends from the BOWMAN CAPSULE in the KIDNEY CORTEX into the KIDNEY MEDULLA. The proximal tubule consists of a convoluted proximal segment in the cortex, and a distal straight segment descending into the medulla where it forms the U-shaped LOOP OF HENLE.
The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments.
The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.
The portion of renal tubule that begins from the enlarged segment of the ascending limb of the LOOP OF HENLE. It reenters the KIDNEY CORTEX and forms the convoluted segments of the distal tubule.
A starch found in the tubers and roots of many plants. Since it is hydrolyzable to FRUCTOSE, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
The functional units of the kidney, consisting of the glomerulus and the attached tubule.
The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
Errors in the metabolism of LIPIDS resulting from inborn genetic MUTATIONS that are heritable.
The movement of materials across cell membranes and epithelial layers against an electrochemical gradient, requiring the expenditure of metabolic energy.
The identification of selected parameters in newborn infants by various tests, examinations, or other procedures. Screening may be performed by clinical or laboratory measures. A screening test is designed to sort out healthy neonates (INFANT, NEWBORN) from those not well, but the screening test is not intended as a diagnostic device, rather instead as epidemiologic.
Inborn errors of purine-pyrimidine metabolism refer to genetic disorders resulting from defects in the enzymes responsible for the metabolic breakdown and synthesis of purines and pyrimidines, leading to the accumulation of toxic metabolites or deficiency of necessary nucleotides, causing various clinical manifestations such as neurological impairment, kidney problems, and developmental delays.
Errors in metabolic processing of STEROIDS resulting from inborn genetic mutations that are inherited or acquired in utero.
A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.
Inborn errors of carbohydrate metabolism are genetic disorders that result from enzyme deficiencies or transport defects in the metabolic pathways responsible for breaking down and processing carbohydrates, leading to accumulation of toxic intermediates or energy deficits, and typically presenting with multisystem clinical manifestations.
Rare congenital metabolism disorders of the urea cycle. The disorders are due to mutations that result in complete (neonatal onset) or partial (childhood or adult onset) inactivity of an enzyme, involved in the urea cycle. Neonatal onset results in clinical features that include irritability, vomiting, lethargy, seizures, NEONATAL HYPOTONIA; RESPIRATORY ALKALOSIS; HYPERAMMONEMIA; coma, and death. Survivors of the neonatal onset and childhood/adult onset disorders share common risks for ENCEPHALOPATHIES, METABOLIC, INBORN; and RESPIRATORY ALKALOSIS due to HYPERAMMONEMIA.
Brain disorders resulting from inborn metabolic errors, primarily from enzymatic defects which lead to substrate accumulation, product reduction, or increase in toxic metabolites through alternate pathways. The majority of these conditions are familial, however spontaneous mutation may also occur in utero.
Rare autosomal recessive disorder of the urea cycle which leads to the accumulation of argininosuccinic acid in body fluids and severe HYPERAMMONEMIA. Clinical features of the neonatal onset of the disorder include poor feeding, vomiting, lethargy, seizures, tachypnea, coma, and death. Later onset results in milder set of clinical features including vomiting, failure to thrive, irritability, behavioral problems, or psychomotor retardation. Mutations in the ARGININOSUCCINATE LYASE gene cause the disorder.
Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
The directed transport of ORGANELLES and molecules along nerve cell AXONS. Transport can be anterograde (from the cell body) or retrograde (toward the cell body). (Alberts et al., Molecular Biology of the Cell, 3d ed, pG3)
The movement of ions across energy-transducing cell membranes. Transport can be active, passive or facilitated. Ions may travel by themselves (uniport), or as a group of two or more ions in the same (symport) or opposite (antiport) directions.
Membrane proteins whose primary function is to facilitate the transport of molecules across a biological membrane. Included in this broad category are proteins involved in active transport (BIOLOGICAL TRANSPORT, ACTIVE), facilitated transport and ION CHANNELS.
A group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme PHENYLALANINE HYDROXYLASE or less frequently by reduced activity of DIHYDROPTERIDINE REDUCTASE (i.e., atypical phenylketonuria). Classical phenylketonuria is caused by a severe deficiency of phenylalanine hydroxylase and presents in infancy with developmental delay; SEIZURES; skin HYPOPIGMENTATION; ECZEMA; and demyelination in the central nervous system. (From Adams et al., Principles of Neurology, 6th ed, p952).
An autosomal recessive disorder of CHOLESTEROL metabolism. It is caused by a deficiency of 7-dehydrocholesterol reductase, the enzyme that converts 7-dehydrocholesterol to cholesterol, leading to an abnormally low plasma cholesterol. This syndrome is characterized by multiple CONGENITAL ABNORMALITIES, growth deficiency, and INTELLECTUAL DISABILITY.
The process of moving proteins from one cellular compartment (including extracellular) to another by various sorting and transport mechanisms such as gated transport, protein translocation, and vesicular transport.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Deviations from the average or standard indices of refraction of the eye through its dioptric or refractive apparatus.
An infant during the first month after birth.
A mononuclear Fe(II)-dependent oxygenase, this enzyme catalyzes the conversion of homogentisate to 4-maleylacetoacetate, the third step in the pathway for the catabolism of TYROSINE. Deficiency in the enzyme causes ALKAPTONURIA, an autosomal recessive disorder, characterized by homogentisic aciduria, OCHRONOSIS and ARTHRITIS. This enzyme was formerly characterized as EC 1.13.1.5 and EC 1.99.2.5.
A clinical syndrome characterized by development, usually in infancy or childhood, of a chronic, often widespread candidiasis of skin, nails, and mucous membranes. It may be secondary to one of the immunodeficiency syndromes, inherited as an autosomal recessive trait, or associated with defects in cell-mediated immunity, endocrine disorders, dental stomatitis, or malignancy.
An enzyme that catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-galactosides including galactose oligosaccharides, galactomannans, and galactolipids.
Hereditary disorders of pyruvate metabolism. They are difficult to diagnose and describe because pyruvate is a key intermediate in glycolysis, gluconeogenesis, and the tricarboxylic acid cycle. Some inherited metabolic disorders may alter pyruvate metabolism indirectly. Disorders in pyruvate metabolism appear to lead to deficiencies in neurotransmitter synthesis and, consequently, to nervous system disorders.
Autosomal recessive inborn error of methionine metabolism usually caused by a deficiency of CYSTATHIONINE BETA-SYNTHASE and associated with elevations of homocysteine in plasma and urine. Clinical features include a tall slender habitus, SCOLIOSIS, arachnodactyly, MUSCLE WEAKNESS, genu varus, thin blond hair, malar flush, lens dislocations, an increased incidence of MENTAL RETARDATION, and a tendency to develop fibrosis of arteries, frequently complicated by CEREBROVASCULAR ACCIDENTS and MYOCARDIAL INFARCTION. (From Adams et al., Principles of Neurology, 6th ed, p979)
An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.
A territory of Australia consisting of Canberra, the national capital and surrounding land. It lies geographically within NEW SOUTH WALES and was established by law in 1988.
An inherited urea cycle disorder associated with deficiency of the enzyme ORNITHINE CARBAMOYLTRANSFERASE, transmitted as an X-linked trait and featuring elevations of amino acids and ammonia in the serum. Clinical features, which are more prominent in males, include seizures, behavioral alterations, episodic vomiting, lethargy, and coma. (Menkes, Textbook of Child Neurology, 5th ed, pp49-50)
This amino acid is formed during the urea cycle from citrulline, aspartate and ATP. This reaction is catalyzed by argininosuccinic acid synthetase.
A mitochondrial flavoprotein, this enzyme catalyzes the oxidation of 3-methylbutanoyl-CoA to 3-methylbut-2-enoyl-CoA using FAD as a cofactor. Defects in the enzyme, is associated with isovaleric acidemia (IVA).
A large group of membrane transport proteins that shuttle MONOSACCHARIDES across CELL MEMBRANES.
A genetic metabolic disorder resulting from serum and bone alkaline phosphatase deficiency leading to hypercalcemia, ethanolamine phosphatemia, and ethanolamine phosphaturia. Clinical manifestations include severe skeletal defects resembling vitamin D-resistant rickets, failure of the calvarium to calcify, dyspnea, cyanosis, vomiting, constipation, renal calcinosis, failure to thrive, disorders of movement, beading of the costochondral junction, and rachitic bone changes. (From Dorland, 27th ed)
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Incorrect diagnoses after clinical examination or technical diagnostic procedures.
Injectable form of VITAMIN B 12 that has been used therapeutically to treat VITAMIN B 12 DEFICIENCY.
A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA.
Acquired or inborn metabolic diseases that produce brain dysfunction or damage. These include primary (i.e., disorders intrinsic to the brain) and secondary (i.e., extracranial) metabolic conditions that adversely affect cerebral function.
Pentanoic acid, also known as valeric acid, is a carboxylic acid with a 5-carbon chain (C5H10O2), having a distinctive pungent and rancid odor, found in some animals' sweat, certain foods, and produced through wood fermentation.
An enzyme that catalyzes the conversion of methylmalonyl-CoA to succinyl-CoA by transfer of the carbonyl group. It requires a cobamide coenzyme. A block in this enzymatic conversion leads to the metabolic disease, methylmalonic aciduria. EC 5.4.99.2.
A constituent of STRIATED MUSCLE and LIVER. It is an amino acid derivative and an essential cofactor for fatty acid metabolism.
A subclass of enzymes which includes all dehydrogenases acting on carbon-carbon bonds. This enzyme group includes all the enzymes that introduce double bonds into substrates by direct dehydrogenation of carbon-carbon single bonds.
The process by which ELECTRONS are transported from a reduced substrate to molecular OXYGEN. (From Bennington, Saunders Dictionary and Encyclopedia of Laboratory Medicine and Technology, 1984, p270)
Inherited abnormalities of fructose metabolism, which include three known autosomal recessive types: hepatic fructokinase deficiency (essential fructosuria), hereditary fructose intolerance, and hereditary fructose-1,6-diphosphatase deficiency. Essential fructosuria is a benign asymptomatic metabolic disorder caused by deficiency in fructokinase, leading to decreased conversion of fructose to fructose-1-phosphate and alimentary hyperfructosemia, but with no clinical dysfunction; may produce a false-positive diabetes test.
The rate dynamics in chemical or physical systems.
Glutarates are organic compounds, specifically carboxylic acids, that contain a five-carbon chain with two terminal carboxyl groups and a central methyl group, playing a role in various metabolic processes, including the breakdown of certain amino acids. They can also refer to their salts or esters. Please note that this definition is concise and may not cover all aspects of glutarates in depth.
An autosomal recessive inherited disorder with multiple forms of phenotypic expression, caused by a defect in the oxidative decarboxylation of branched-chain amino acids (AMINO ACIDS, BRANCHED-CHAIN). These metabolites accumulate in body fluids and render a "maple syrup" odor. The disease is divided into classic, intermediate, intermittent, and thiamine responsive subtypes. The classic form presents in the first week of life with ketoacidosis, hypoglycemia, emesis, neonatal seizures, and hypertonia. The intermediate and intermittent forms present in childhood or later with acute episodes of ataxia and vomiting. (From Adams et al., Principles of Neurology, 6th ed, p936)
An autosomal recessive porphyria that is due to a deficiency of UROPORPHYRINOGEN III SYNTHASE in the BONE MARROW; also known as congenital erythropoietic porphyria. This disease is characterized by SPLENOMEGALY; ANEMIA; photosensitivity; cutaneous lesions; accumulation of hydroxymethylbilane; and increased excretion of UROPORPHYRINS and COPROPORPHYRINS.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
A flavoprotein enzyme that is responsible for the catabolism of LYSINE; HYDROXYLYSINE; and TRYPTOPHAN. It catalyzes the oxidation of GLUTARYL-CoA to crotonoyl-CoA using FAD as a cofactor. Glutaric aciduria type I is an inborn error of metabolism due to the deficiency of glutaryl-CoA dehydrogenase.
Enzymes of a subclass of TRANSFERASES that catalyze the transfer of an amidino group from donor to acceptor. EC 2.1.4.
Inborn errors of metal metabolism refer to genetic disorders resulting from mutations in genes encoding proteins involved in the transportation, storage, or utilization of essential metals, leading to imbalances that can cause toxicity or deficiency and subsequent impairment of normal physiological processes.
Transport proteins that carry specific substances in the blood or across cell membranes.
A condition of substandard growth or diminished capacity to maintain normal function.
A rare autosomal recessive disorder of the urea cycle. It is caused by a deficiency of the hepatic enzyme ARGINASE. Arginine is elevated in the blood and cerebrospinal fluid, and periodic HYPERAMMONEMIA may occur. Disease onset is usually in infancy or early childhood. Clinical manifestations include seizures, microcephaly, progressive mental impairment, hypotonia, ataxia, spastic diplegia, and quadriparesis. (From Hum Genet 1993 Mar;91(1):1-5; Menkes, Textbook of Child Neurology, 5th ed, p51)
An NAD-dependent 3-hydroxyacyl CoA dehydrogenase that has specificity for acyl chains containing 8 and 10 carbons.
Vesicles that are involved in shuttling cargo from the interior of the cell to the cell surface, from the cell surface to the interior, across the cell or around the cell to various locations.
An inborn error of amino acid metabolism resulting from a defect in the enzyme HOMOGENTISATE 1,2-DIOXYGENASE, an enzyme involved in the breakdown of PHENYLALANINE and TYROSINE. It is characterized by accumulation of HOMOGENTISIC ACID in the urine, OCHRONOSIS in various tissues, and ARTHRITIS.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A large group of diseases which are characterized by a low prevalence in the population. They frequently are associated with problems in diagnosis and treatment.
A group of diseases related to a deficiency of the enzyme ARGININOSUCCINATE SYNTHASE which causes an elevation of serum levels of CITRULLINE. In neonates, clinical manifestations include lethargy, hypotonia, and SEIZURES. Milder forms also occur. Childhood and adult forms may present with recurrent episodes of intermittent weakness, lethargy, ATAXIA, behavioral changes, and DYSARTHRIA. (From Menkes, Textbook of Child Neurology, 5th ed, p49)
An autosomal recessive disorder of fatty acid oxidation, and branched chain amino acids (AMINO ACIDS, BRANCHED-CHAIN); LYSINE; and CHOLINE catabolism, that is due to defects in either subunit of ELECTRON TRANSFER FLAVOPROTEIN or its dehydrogenase, electron transfer flavoprotein-ubiquinone oxidoreductase (EC 1.5.5.1).
Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins.
The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency.
Disorders in the processing of iron in the body: its absorption, transport, storage, and utilization. (From Mosby's Medical, Nursing, & Allied Health Dictionary, 4th ed)
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Inborn errors of metabolism characterized by defects in specific lysosomal hydrolases and resulting in intracellular accumulation of unmetabolized substrates.
An inherited metabolic disorder caused by deficient enzyme activity in the PYRUVATE DEHYDROGENASE COMPLEX, resulting in deficiency of acetyl CoA and reduced synthesis of acetylcholine. Two clinical forms are recognized: neonatal and juvenile. The neonatal form is a relatively common cause of lactic acidosis in the first weeks of life and may also feature an erythematous rash. The juvenile form presents with lactic acidosis, alopecia, intermittent ATAXIA; SEIZURES; and an erythematous rash. (From J Inherit Metab Dis 1996;19(4):452-62) Autosomal recessive and X-linked forms are caused by mutations in the genes for the three different enzyme components of this multisubunit pyruvate dehydrogenase complex. One of the mutations at Xp22.2-p22.1 in the gene for the E1 alpha component of the complex leads to LEIGH DISEASE.
An enzyme that, in the course of purine ribonucleotide biosynthesis, catalyzes the conversion of 5'-phosphoribosyl-4-(N-succinocarboxamide)-5-aminoimidazole to 5'-phosphoribosyl-4-carboxamide-5-aminoimidazole and the conversion of adenylosuccinic acid to AMP. EC 4.3.2.2.
A nonspecific term referring both to the pathologic finding of swelling of distal portions of axons in the brain and to disorders which feature this finding. Neuroaxonal dystrophy is seen in various genetic diseases, vitamin deficiencies, and aging. Infantile neuroaxonal dystrophy is an autosomal recessive disease characterized by arrested psychomotor development at 6 months to 2 years of age, ataxia, brain stem dysfunction, and quadriparesis. Juvenile and adult forms also occur. Pathologic findings include brain atrophy and widespread accumulation of axonal spheroids throughout the neuroaxis, peripheral nerves, and dental pulp. (From Davis & Robertson, Textbook of Neuropathology, 2nd ed, p927)
A pyridoxal phosphate enzyme that catalyzes the formation of glutamate gamma-semialdehyde and an L-amino acid from L-ornithine and a 2-keto-acid. EC 2.6.1.13.
Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.
Membrane proteins whose primary function is to facilitate the transport of negatively charged molecules (anions) across a biological membrane.
A flavoprotein oxidoreductase that has specificity for medium-chain fatty acids. It forms a complex with ELECTRON TRANSFERRING FLAVOPROTEINS and conveys reducing equivalents to UBIQUINONE.
A genetic disorder characterized by excretion of large amounts of OXALATES in urine; NEPHROLITHIASIS; NEPHROCALCINOSIS; early onset of RENAL FAILURE; and often a generalized deposit of CALCIUM OXALATE. There are subtypes classified by the enzyme defects in glyoxylate metabolism.
Membrane proteins whose primary function is to facilitate the transport of positively charged molecules (cations) across a biological membrane.

Lowe's syndrome: identification of carriers by lens examination. (1/53)

Lens examinations were performed on 7 obligate and 7 possible carriers of the X-linked gene for Lowe's syndrome, and on 117 controls. By quantitatively grading punctate cortical opacities, it was possible to discriminate between the obligate carriers and the controls with a fair degree of confidence. In the age group most important for genetic counselling, that of child bearing, the data are too limited for the derivation of precise estimates, but may, nevertheless, be useful. More such data are needed.  (+info)

Magnesium transport in the renal distal convoluted tubule. (2/53)

The distal tubule reabsorbs approximately 10% of the filtered Mg(2+), but this is 70-80% of that delivered from the loop of Henle. Because there is little Mg(2+) reabsorption beyond the distal tubule, this segment plays an important role in determining the final urinary excretion. The distal convoluted segment (DCT) is characterized by a negative luminal voltage and high intercellular resistance so that Mg(2+) reabsorption is transcellular and active. This review discusses recent evidence for selective and sensitive control of Mg(2+) transport in the DCT and emphasizes the importance of this control in normal and abnormal renal Mg(2+) conservation. Normally, Mg(2+) absorption is load dependent in the distal tubule, whether delivery is altered by increasing luminal Mg(2+) concentration or increasing the flow rate into the DCT. With the use of microfluorescent studies with an established mouse distal convoluted tubule (MDCT) cell line, it was shown that Mg(2+) uptake was concentration and voltage dependent. Peptide hormones such as parathyroid hormone, calcitonin, glucagon, and arginine vasopressin enhance Mg(2+) absorption in the distal tubule and stimulate Mg(2+) uptake into MDCT cells. Prostaglandin E(2) and isoproterenol increase Mg(2+) entry into MDCT cells. The current evidence indicates that cAMP-dependent protein kinase A, phospholipase C, and protein kinase C signaling pathways are involved in these responses. Steroid hormones have significant effects on distal Mg(2+) transport. Aldosterone does not alter basal Mg(2+) uptake but potentiates hormone-stimulated Mg(2+) entry in MDCT cells by increasing hormone-mediated cAMP formation. 1,25-Dihydroxyvitamin D(3), on the other hand, stimulates basal Mg(2+) uptake. Elevation of plasma Mg(2+) or Ca(2+) inhibits hormone-stimulated cAMP accumulation and Mg(2+) uptake in MDCT cells through activation of extracellular Ca(2+)/Mg(2+)-sensing mechanisms. Mg(2+) restriction selectively increases Mg(2+) uptake with no effect on Ca(2+) absorption. This intrinsic cellular adaptation provides the sensitive and selective control of distal Mg(2+) transport. The distally acting diuretics amiloride and chlorothiazide stimulate Mg(2+) uptake in MDCT cells acting through changes in membrane voltage. A number of familial and acquired disorders have been described that emphasize the diversity of cellular controls affecting renal Mg(2+) balance. Although it is clear that many influences affect Mg(2+) transport within the DCT, the transport processes have not been identified.  (+info)

Localization of the membrane defect in transepithelial transport of taurine by parallel studies in vivo and in vitro in hypertaurinuric mice. (3/53)

We investigated the mechanism of taurinuria in three inbred strains of mice: A/J, a normal taurine excretor (taut+); and two hypertaurinuric (taut-) strains, C57BL/6J and PRO/Re. Plasma taurine is comparable in the three strains (approximately 0.5 mM), but taurinuria is 10-fold greater in taut- animals. Fractional reabsorption of taurine is 0.967 +/- 0.013 (mean +/- SD) in A/J); and 0.839 +/- 0.08 and 0.787 +/- 0.05 in C57BL/6J and PRO/Re, respectively. Taurine concentration in renal cortex intracellular fluid (free of urine contamination) is similar in the three strains. Taurine reabsorption is inhibited by beta-alanine, in taut+ and taut- strains. These in vivo findings reveal residual taurine transport activity in the taut- phenotype and no evidence for impaired efflux at basilar membranes as the cause of impaired taurine reabsorption. Cortex slices provide information about uptake of amino acids at the antiluminal membrane. Taurine behaves as an inert metabolite in mouse kidney cortex slices. Taurine uptake by slices is active and, at less than 1 mM, is greater than normal in taut- slices. Concentration-dependent uptake studies reveal more than one taurine carrier in taut+ and taut- strains. The apparent Km values for uptake below 1 mM are different in taut- and taut+ slices (approximately 0.2 mM and approximately 0.7 mM, respectively); the apparent Km values above 1 mM taurine are similar in taut+ and taut- slices. Efflux from slices in all strains in the same (0.0105-0.0113 mumol-min-1-g-1 wet wt), but taut- tissue retains about 10% more radioactivity over the period of efflux. beta-Alanine is actively metabolized in mouse kidney. Its uptake in the presence of blocked transamination, is greater; its intracellular oxidation is attenuated; and its exchange with intracellular taurine is diminished in taut- slices. These findings indicate impaired beta-amino acid permeation on a low-Km uptake system at the luminal membrane in the taut- phenotype. beta-Amino acids are not reclaimed efficiently either from the innermost luminal pool in cortex slices or from the ultrafiltrate in the tubule lumen in vivo. The former leads to high uptake ratios in vitro, the latter to high clearance rates in vivo. In vitro and in vivo data are thus concordant. This is the first time that a hereditary defect in amino acid transport has been assigned to a specific membrane surface in mammalian kidney.  (+info)

Dent Disease with mutations in OCRL1. (4/53)

Dent disease is an X-linked renal proximal tubulopathy associated with mutations in the chloride channel gene CLCN5. Lowe syndrome, a multisystem disease characterized by renal tubulopathy, congenital cataracts, and mental retardation, is associated with mutations in the gene OCRL1, which encodes a phosphatidylinositol 4,5-bisphosphate (PIP(2)) 5-phosphatase. Genetic heterogeneity has been suspected in Dent disease, but no other gene for Dent disease has been reported. We studied male probands in 13 families, all of whom met strict criteria for Dent disease but lacked mutations in CLCN5. Linkage analysis in the one large family localized the gene to a candidate region at Xq25-Xq27.1. Sequencing of candidate genes revealed a mutation in the OCRL1 gene. Of the 13 families studied, OCRL1 mutations were found in 5. PIP(2) 5-phosphatase activity was markedly reduced in skin fibroblasts cultured from the probands of these five families, and protein expression, measured by western blotting, was reduced or absent. Slit-lamp examinations performed in childhood or adulthood for all five probands showed normal results. Unlike patients with typical Lowe syndrome, none of these patients had metabolic acidosis. Three of the five probands had mild mental retardation, whereas two had no developmental delay or behavioral disturbance. These findings demonstrate that mutations in OCRL1 can occur with the isolated renal phenotype of Dent disease in patients lacking the cataracts, renal tubular acidosis, and neurological abnormalities that are characteristic of Lowe syndrome. This observation confirms genetic heterogeneity in Dent disease and demonstrates more-extensive phenotypic heterogeneity in Lowe syndrome than was previously appreciated. It establishes that the diagnostic criteria for disorders resulting from mutations in the Lowe syndrome gene OCRL1 need to be revised.  (+info)

Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. (5/53)

Thiazide diuretics enhance renal Na+ excretion by blocking the Na+-Cl- cotransporter (NCC), and mutations in NCC result in Gitelman syndrome. The mechanisms underlying the accompanying hypocalciuria and hypomagnesemia remain debated. Here, we show that enhanced passive Ca2+ transport in the proximal tubule rather than active Ca2+ transport in distal convolution explains thiazide-induced hypocalciuria. First, micropuncture experiments in mice demonstrated increased reabsorption of Na+ and Ca2+ in the proximal tubule during chronic hydrochlorothiazide (HCTZ) treatment, whereas Ca2+ reabsorption in distal convolution appeared unaffected. Second, HCTZ administration still induced hypocalciuria in transient receptor potential channel subfamily V, member 5-knockout (Trpv5-knockout) mice, in which active distal Ca2+ reabsorption is abolished due to inactivation of the epithelial Ca2+ channel Trpv5. Third, HCTZ upregulated the Na+/H+ exchanger, responsible for the majority of Na+ and, consequently, Ca2+ reabsorption in the proximal tubule, while the expression of proteins involved in active Ca2+ transport was unaltered. Fourth, experiments addressing the time-dependent effect of a single dose of HCTZ showed that the development of hypocalciuria parallels a compensatory increase in Na+ reabsorption secondary to an initial natriuresis. Hypomagnesemia developed during chronic HCTZ administration and in NCC-knockout mice, an animal model of Gitelman syndrome, accompanied by downregulation of the epithelial Mg2+ channel transient receptor potential channel subfamily M, member 6 (Trpm6). Thus, Trpm6 downregulation may represent a general mechanism involved in the pathogenesis of hypomagnesemia accompanying NCC inhibition or inactivation.  (+info)

When EGF is offside, magnesium is wasted. (6/53)

Our understanding of magnesium (Mg(2+)) regulation has recently been catapulted forward by the discovery of several disease loci for monogenic disorders of Mg(2+) homeostasis. In this issue of the JCI, Groenestege et al. report that their study of a rare inherited Mg(2+) wasting disorder in consanguineous kindred shows that EGF acts as an autocrine/paracrine magnesiotropic hormone (see the related article beginning on page 2260). EGF stimulates Mg(2+) reabsorption in the renal distal convoluted tubule (DCT) via engagement of its receptor on the basolateral membrane of DCT cells and activation of the Mg(2+) channel TRPM6 (transient receptor potential cation channel, subfamily M, member 6) in the apical membrane. These authors show that a point mutation in pro-EGF retains EGF secretion to the apical but not the basolateral membrane, disrupting this cascade and causing renal Mg(2+) wasting. This work is another seminal example of the power of the study of monogenic disorders in the quest to understand human physiology.  (+info)

Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. (7/53)

Primary hypomagnesemia constitutes a rare heterogeneous group of disorders characterized by renal or intestinal magnesium (Mg(2+)) wasting resulting in generally shared symptoms of Mg(2+) depletion, such as tetany and generalized convulsions, and often including associated disturbances in calcium excretion. However, most of the genes involved in the physiology of Mg(2+) handling are unknown. Through the discovery of a mutation in the EGF gene in isolated autosomal recessive renal hypomagnesemia, we have, for what we believe is the first time, identified a magnesiotropic hormone crucial for total body Mg(2+) balance. The mutation leads to impaired basolateral sorting of pro-EGF. As a consequence, the renal EGFR is inadequately stimulated, resulting in insufficient activation of the epithelial Mg(2+) channel TRPM6 (transient receptor potential cation channel, subfamily M, member 6) and thereby Mg(2+) loss. Furthermore, we show that colorectal cancer patients treated with cetuximab, an antagonist of the EGFR, develop hypomagnesemia, emphasizing the significance of EGF in maintaining Mg(2+) balance.  (+info)

Human FXYD2 G41R mutation responsible for renal hypomagnesemia behaves as an inward-rectifying cation channel. (8/53)

 (+info)

Inborn errors of renal tubular transport refer to genetic disorders that affect the normal functioning of the kidney tubules. The kidney tubules are responsible for the reabsorption and secretion of various substances, including electrolytes and nutrients, as urine is formed. Inherited defects in the proteins that mediate these transport processes can lead to abnormal levels of these substances in the body and may result in a variety of clinical symptoms.

These disorders can affect different parts of the renal tubule, including the proximal tubule, loop of Henle, distal tubule, and collecting duct. Depending on the specific transporter affected, inborn errors of renal tubular transport can present with a range of clinical manifestations, such as electrolyte imbalances, acid-base disorders, growth retardation, kidney stones, nephrocalcinosis, or even kidney failure.

Examples of inborn errors of renal tubular transport include:

1. Distal renal tubular acidosis (dRTA): A genetic disorder that affects the ability of the distal tubule to acidify urine, leading to metabolic acidosis, hypokalemia, and nephrocalcinosis.
2. Bartter syndrome: A group of autosomal recessive disorders characterized by impaired sodium reabsorption in the loop of Henle, resulting in hypokalemia, metabolic alkalosis, and hyperreninemic hyperaldosteronism.
3. Gitelman syndrome: An autosomal recessive disorder caused by a defect in the thiazide-sensitive sodium chloride cotransporter in the distal tubule, leading to hypokalemia, metabolic alkalosis, and hypocalciuria.
4. Liddle syndrome: An autosomal dominant disorder characterized by increased sodium reabsorption in the collecting duct due to a gain-of-function mutation in the epithelial sodium channel (ENaC), resulting in hypertension, hypokalemia, and metabolic alkalosis.
5. Dent disease: An X-linked recessive disorder caused by mutations in the CLCN5 gene, which encodes a chloride channel in the proximal tubule, leading to low molecular weight proteinuria, hypercalciuria, and nephrolithiasis.
6. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC): An autosomal recessive disorder caused by mutations in the CLCN5 or CLDN16 genes, which encode chloride channels in the thick ascending limb of Henle's loop, resulting in hypomagnesemia, hypercalciuria, and nephrocalcinosis.

Probenecid is a medication that is primarily used to treat gout and hyperuricemia (high levels of uric acid in the blood). It works by decreasing the production of uric acid in the body and increasing its excretion through the kidneys.

In medical terms, probenecid is a uricosuric agent, which means it increases the urinary excretion of urate, the salt form of uric acid. It does this by inhibiting the reabsorption of urate in the proximal tubules of the kidneys, thereby promoting its elimination in the urine.

Probenecid is also used in conjunction with certain antibiotics, such as penicillin and cephalosporins, to increase their concentration in the body by reducing their excretion by the kidneys. This is known as probenecid-antibiotic interaction.

It's important to note that probenecid should be used under the supervision of a healthcare provider, and its use may be contraindicated in certain medical conditions or in combination with specific medications.

Renal aminoacidurias are a group of inherited kidney disorders characterized by the abnormal excretion of amino acids in the urine (aminoaciduria). This condition results from defects in the renal tubular transport systems that are responsible for the reabsorption of amino acids from the filtrate in the kidneys.

There are several types of renal aminoacidurias, each associated with a specific genetic mutation affecting different transporter proteins in the proximal renal tubules. The most common type is cystinuria, which is caused by a defect in the transport system for four amino acids: cystine, ornithine, lysine, and arginine. Other types of renal aminoacidurias include Hartnup disorder, Lowe syndrome, and Dent disease, among others.

The clinical manifestations of renal aminoacidurias vary depending on the specific type and severity of the disorder. Some individuals may be asymptomatic or have only mild symptoms, while others may experience severe complications such as kidney stones, urinary tract infections, neurological symptoms, or growth retardation.

Treatment for renal aminoacidurias typically involves dietary modifications, increased fluid intake, and medications to reduce the risk of kidney stone formation and other complications. In some cases, surgery may be necessary to remove large kidney stones.

Kidney tubules are the structural and functional units of the kidney responsible for reabsorption, secretion, and excretion of various substances. They are part of the nephron, which is the basic unit of the kidney's filtration and reabsorption process.

There are three main types of kidney tubules:

1. Proximal tubule: This is the initial segment of the kidney tubule that receives the filtrate from the glomerulus. It is responsible for reabsorbing approximately 65% of the filtrate, including water, glucose, amino acids, and electrolytes.
2. Loop of Henle: This U-shaped segment of the tubule consists of a thin descending limb, a thin ascending limb, and a thick ascending limb. The loop of Henle helps to concentrate urine by creating an osmotic gradient that allows water to be reabsorbed in the collecting ducts.
3. Distal tubule: This is the final segment of the kidney tubule before it empties into the collecting duct. It is responsible for fine-tuning the concentration of electrolytes and pH balance in the urine by selectively reabsorbing or secreting substances such as sodium, potassium, chloride, and hydrogen ions.

Overall, kidney tubules play a critical role in maintaining fluid and electrolyte balance, regulating acid-base balance, and removing waste products from the body.

Inborn errors of metabolism (IEM) refer to a group of genetic disorders caused by defects in enzymes or transporters that play a role in the body's metabolic processes. These disorders result in the accumulation or deficiency of specific chemicals within the body, which can lead to various clinical manifestations, such as developmental delay, intellectual disability, seizures, organ damage, and in some cases, death.

Examples of IEM include phenylketonuria (PKU), maple syrup urine disease (MSUD), galactosemia, and glycogen storage diseases, among many others. These disorders are typically inherited in an autosomal recessive manner, meaning that an affected individual has two copies of the mutated gene, one from each parent.

Early diagnosis and management of IEM are crucial to prevent or minimize complications and improve outcomes. Treatment options may include dietary modifications, supplementation with missing enzymes or cofactors, medication, and in some cases, stem cell transplantation or gene therapy.

Aminohippuric acids are a type of organic compound that contain both an amino group and a hippuric acid group in their chemical structure. Hippuric acid is a derivative of benzoic acid, which is conjugated with glycine in the body. Aminohippuric acids are primarily known for their use as diagnostic agents in renal function tests.

The most common aminohippuric acid is p-aminohippuric acid (PAH), which is used as a marker to measure effective renal plasma flow (ERPF) in the kidneys. PAH is freely filtered by the glomeruli and then actively secreted by the proximal tubules of the nephrons, making it an ideal agent for measuring ERPF.

In a renal function test using PAH, a small dose of the compound is injected into the patient's bloodstream, and its concentration in the blood is measured over time. By analyzing the clearance rate of PAH from the blood, healthcare providers can estimate the ERPF and assess kidney function.

Overall, aminohippuric acids are important diagnostic tools for evaluating renal function and identifying potential kidney-related health issues.

Inborn errors of amino acid metabolism refer to genetic disorders that affect the body's ability to properly break down and process individual amino acids, which are the building blocks of proteins. These disorders can result in an accumulation of toxic levels of certain amino acids or their byproducts in the body, leading to a variety of symptoms and health complications.

There are many different types of inborn errors of amino acid metabolism, each affecting a specific amino acid or group of amino acids. Some examples include:

* Phenylketonuria (PKU): This disorder affects the breakdown of the amino acid phenylalanine, leading to its accumulation in the body and causing brain damage if left untreated.
* Maple syrup urine disease: This disorder affects the breakdown of the branched-chain amino acids leucine, isoleucine, and valine, leading to their accumulation in the body and causing neurological problems.
* Homocystinuria: This disorder affects the breakdown of the amino acid methionine, leading to its accumulation in the body and causing a range of symptoms including developmental delay, intellectual disability, and cardiovascular problems.

Treatment for inborn errors of amino acid metabolism typically involves dietary restrictions or supplementation to manage the levels of affected amino acids in the body. In some cases, medication or other therapies may also be necessary. Early diagnosis and treatment can help prevent or minimize the severity of symptoms and health complications associated with these disorders.

The proximal kidney tubule is the initial portion of the renal tubule in the nephron of the kidney. It is located in the renal cortex and is called "proximal" because it is closer to the glomerulus, compared to the distal tubule. The proximal tubule plays a crucial role in the reabsorption of water, electrolytes, and nutrients from the filtrate that has been formed by the glomerulus. It also helps in the secretion of waste products and other substances into the urine.

The proximal tubule is divided into two segments: the pars convoluta and the pars recta. The pars convoluta is the curved portion that receives filtrate from the Bowman's capsule, while the pars recta is the straight portion that extends deeper into the renal cortex.

The proximal tubule is lined with a simple cuboidal epithelium, and its cells are characterized by numerous mitochondria, which provide energy for active transport processes. The apical surface of the proximal tubular cells has numerous microvilli, forming a brush border that increases the surface area for reabsorption.

In summary, the proximal kidney tubule is a critical site for the reabsorption of water, electrolytes, and nutrients from the glomerular filtrate, contributing to the maintenance of fluid and electrolyte balance in the body.

Biological transport refers to the movement of molecules, ions, or solutes across biological membranes or through cells in living organisms. This process is essential for maintaining homeostasis, regulating cellular functions, and enabling communication between cells. There are two main types of biological transport: passive transport and active transport.

Passive transport does not require the input of energy and includes:

1. Diffusion: The random movement of molecules from an area of high concentration to an area of low concentration until equilibrium is reached.
2. Osmosis: The diffusion of solvent molecules (usually water) across a semi-permeable membrane from an area of lower solute concentration to an area of higher solute concentration.
3. Facilitated diffusion: The assisted passage of polar or charged substances through protein channels or carriers in the cell membrane, which increases the rate of diffusion without consuming energy.

Active transport requires the input of energy (in the form of ATP) and includes:

1. Primary active transport: The direct use of ATP to move molecules against their concentration gradient, often driven by specific transport proteins called pumps.
2. Secondary active transport: The coupling of the movement of one substance down its electrochemical gradient with the uphill transport of another substance, mediated by a shared transport protein. This process is also known as co-transport or counter-transport.

p-Aminohippuric acid (PAH) is a small organic compound that is primarily used as a diagnostic agent in measuring renal plasma flow. It is freely filtered by the glomeruli and almost completely secreted by the proximal tubules of the kidney. This makes it an ideal candidate for measuring effective renal plasma flow, as changes in its clearance can indicate alterations in renal function.

In a medical context, PAH is often used in conjunction with other tests to help diagnose and monitor kidney diseases or conditions that affect renal function. The compound is typically administered intravenously, and its clearance is then measured through blood or urine samples collected over a specific period. This information can be used to calculate the renal plasma flow and assess the overall health of the kidneys.

It's important to note that while PAH is a valuable tool in clinical nephrology, it should be used as part of a comprehensive diagnostic workup and interpreted in conjunction with other test results and clinical findings.

Distal kidney tubules are the final segment of the renal tubule in the nephron of the kidney. The nephron is the basic unit of the kidney that filters blood and produces urine. After the filtrate leaves the glomerulus, it enters the proximal tubule where most of the reabsorption of water, electrolytes, and nutrients occurs.

The filtrate then moves into the loop of Henle, which is divided into a thin and thick descending limb and a thin and thick ascending limb. The loop of Henle helps to establish a concentration gradient in the medullary interstitium, allowing for the reabsorption of water in the collecting ducts.

The distal tubule is the last segment of the renal tubule before the filtrate enters the collecting duct. It is a relatively short structure that receives filtrate from the thick ascending limb of the loop of Henle. The distal tubule plays an important role in regulating electrolyte and water balance by actively transporting ions such as sodium, potassium, and chloride.

The distal tubule also contains specialized cells called principal cells and intercalated cells that are responsible for secreting or reabsorbing hydrogen and potassium ions to maintain acid-base balance. Additionally, the distal tubule is a site of action for several hormones, including aldosterone, which stimulates sodium reabsorption and potassium excretion, and vasopressin (antidiuretic hormone), which promotes water reabsorption in the collecting ducts.

Inulin is a soluble fiber that is not digestible by human enzymes. It is a fructan, a type of carbohydrate made up of chains of fructose molecules, and is found in various plants such as chicory root, Jerusalem artichokes, and onions.

Inulin has a number of potential health benefits, including promoting the growth of beneficial bacteria in the gut (prebiotic effect), slowing down the absorption of sugar to help regulate blood glucose levels, and increasing feelings of fullness to aid in weight management. It is often used as a functional food ingredient or dietary supplement for these purposes.

Inulin can also be used as a diagnostic tool in medical testing to measure kidney function, as it is excreted unchanged in the urine.

A kidney, in medical terms, is one of two bean-shaped organs located in the lower back region of the body. They are essential for maintaining homeostasis within the body by performing several crucial functions such as:

1. Regulation of water and electrolyte balance: Kidneys help regulate the amount of water and various electrolytes like sodium, potassium, and calcium in the bloodstream to maintain a stable internal environment.

2. Excretion of waste products: They filter waste products from the blood, including urea (a byproduct of protein metabolism), creatinine (a breakdown product of muscle tissue), and other harmful substances that result from normal cellular functions or external sources like medications and toxins.

3. Endocrine function: Kidneys produce several hormones with important roles in the body, such as erythropoietin (stimulates red blood cell production), renin (regulates blood pressure), and calcitriol (activated form of vitamin D that helps regulate calcium homeostasis).

4. pH balance regulation: Kidneys maintain the proper acid-base balance in the body by excreting either hydrogen ions or bicarbonate ions, depending on whether the blood is too acidic or too alkaline.

5. Blood pressure control: The kidneys play a significant role in regulating blood pressure through the renin-angiotensin-aldosterone system (RAAS), which constricts blood vessels and promotes sodium and water retention to increase blood volume and, consequently, blood pressure.

Anatomically, each kidney is approximately 10-12 cm long, 5-7 cm wide, and 3 cm thick, with a weight of about 120-170 grams. They are surrounded by a protective layer of fat and connected to the urinary system through the renal pelvis, ureters, bladder, and urethra.

A nephron is the basic structural and functional unit of the kidney. It is responsible for filtering blood, reabsorbing necessary substances, and excreting waste products into the urine. Each human kidney contains approximately one million nephrons.

The structure of a nephron includes a glomerulus, which is a tuft of capillaries surrounded by Bowman's capsule. The glomerulus filters blood, allowing small molecules like water and solutes to pass through while keeping larger molecules like proteins and blood cells within the capillaries.

The filtrate then passes through the tubular portion of the nephron, which includes the proximal convoluted tubule, loop of Henle, distal convoluted tubule, and collecting duct. The tubular portion reabsorbs necessary substances like water, glucose, amino acids, and electrolytes back into the bloodstream while excreting waste products like urea and creatinine into the urine.

Overall, nephrons play a critical role in maintaining fluid and electrolyte balance, regulating blood pressure, and removing waste products from the body.

In medicine, "absorption" refers to the process by which substances, including nutrients, medications, or toxins, are taken up and assimilated into the body's tissues or bloodstream after they have been introduced into the body via various routes (such as oral, intravenous, or transdermal).

The absorption of a substance depends on several factors, including its chemical properties, the route of administration, and the presence of other substances that may affect its uptake. For example, some medications may be better absorbed when taken with food, while others may require an empty stomach for optimal absorption.

Once a substance is absorbed into the bloodstream, it can then be distributed to various tissues throughout the body, where it may exert its effects or be metabolized and eliminated by the body's detoxification systems. Understanding the process of absorption is crucial in developing effective medical treatments and determining appropriate dosages for medications.

Inborn errors of lipid metabolism refer to genetic disorders that affect the body's ability to break down and process lipids (fats) properly. These disorders are caused by defects in genes that code for enzymes or proteins involved in lipid metabolism. As a result, toxic levels of lipids or their intermediates may accumulate in the body, leading to various health issues, which can include neurological problems, liver dysfunction, muscle weakness, and cardiovascular disease.

There are several types of inborn errors of lipid metabolism, including:

1. Disorders of fatty acid oxidation: These disorders affect the body's ability to convert long-chain fatty acids into energy, leading to muscle weakness, hypoglycemia, and cardiomyopathy. Examples include medium-chain acyl-CoA dehydrogenase deficiency (MCAD) and very long-chain acyl-CoA dehydrogenase deficiency (VLCAD).
2. Disorders of cholesterol metabolism: These disorders affect the body's ability to process cholesterol, leading to an accumulation of cholesterol or its intermediates in various tissues. Examples include Smith-Lemli-Opitz syndrome and lathosterolosis.
3. Disorders of sphingolipid metabolism: These disorders affect the body's ability to break down sphingolipids, leading to an accumulation of these lipids in various tissues. Examples include Gaucher disease, Niemann-Pick disease, and Fabry disease.
4. Disorders of glycerophospholipid metabolism: These disorders affect the body's ability to break down glycerophospholipids, leading to an accumulation of these lipids in various tissues. Examples include rhizomelic chondrodysplasia punctata and abetalipoproteinemia.

Inborn errors of lipid metabolism are typically diagnosed through genetic testing and biochemical tests that measure the activity of specific enzymes or the levels of specific lipids in the body. Treatment may include dietary modifications, supplements, enzyme replacement therapy, or gene therapy, depending on the specific disorder and its severity.

Biological transport, active is the process by which cells use energy to move materials across their membranes from an area of lower concentration to an area of higher concentration. This type of transport is facilitated by specialized proteins called transporters or pumps that are located in the cell membrane. These proteins undergo conformational changes to physically carry the molecules through the lipid bilayer of the membrane, often against their concentration gradient.

Active transport requires energy because it works against the natural tendency of molecules to move from an area of higher concentration to an area of lower concentration, a process known as diffusion. Cells obtain this energy in the form of ATP (adenosine triphosphate), which is produced through cellular respiration.

Examples of active transport include the uptake of glucose and amino acids into cells, as well as the secretion of hormones and neurotransmitters. The sodium-potassium pump, which helps maintain resting membrane potential in nerve and muscle cells, is a classic example of an active transporter.

Neonatal screening is a medical procedure in which specific tests are performed on newborn babies within the first few days of life to detect certain congenital or inherited disorders that are not otherwise clinically apparent at birth. These conditions, if left untreated, can lead to serious health problems, developmental delays, or even death.

The primary goal of neonatal screening is to identify affected infants early so that appropriate treatment and management can be initiated as soon as possible, thereby improving their overall prognosis and quality of life. Commonly screened conditions include phenylketonuria (PKU), congenital hypothyroidism, galactosemia, maple syrup urine disease, sickle cell disease, cystic fibrosis, and hearing loss, among others.

Neonatal screening typically involves collecting a small blood sample from the infant's heel (heel stick) or through a dried blood spot card, which is then analyzed using various biochemical, enzymatic, or genetic tests. In some cases, additional tests such as hearing screenings and pulse oximetry for critical congenital heart disease may also be performed.

It's important to note that neonatal screening is not a diagnostic tool but rather an initial step in identifying infants who may be at risk of certain conditions. Positive screening results should always be confirmed with additional diagnostic tests before any treatment decisions are made.

Inborn errors of purine-pyrimidine metabolism refer to genetic disorders that result in dysfunctional enzymes involved in the metabolic pathways of purines and pyrimidines. These are essential components of nucleotides, which in turn are building blocks of DNA and RNA.

Inherited as autosomal recessive or X-linked recessive traits, these disorders can lead to an accumulation of toxic metabolites, a deficiency of necessary compounds, or both. Clinical features vary widely depending on the specific enzyme defect but may include neurologic symptoms, kidney problems, gout, and/or immunodeficiency.

Examples of such disorders include Lesch-Nyhan syndrome (deficiency of hypoxanthine-guanine phosphoribosyltransferase), adenosine deaminase deficiency (leading to severe combined immunodeficiency), and orotic aciduria (due to defects in pyrimidine metabolism). Early diagnosis and management are crucial to improve outcomes.

Inborn errors of steroid metabolism refer to genetic disorders that affect the synthesis or degradation of steroid hormones in the body. Steroids are a group of hormones that include cortisol, aldosterone, sex hormones (estrogens and androgens), and bile acids. These hormones are produced through a series of biochemical reactions called steroidogenesis, which involves several enzymes.

Inborn errors of steroid metabolism occur when there is a mutation in the gene encoding for one or more of these enzymes, leading to impaired steroid synthesis or degradation. This can result in an accumulation of abnormal steroid metabolites or deficiency of essential steroid hormones, causing various clinical manifestations depending on the specific steroid hormone affected and the severity of the enzyme deficiency.

Examples of inborn errors of steroid metabolism include congenital adrenal hyperplasia (CAH), which is caused by defects in the genes encoding for enzymes involved in cortisol synthesis, such as 21-hydroxylase and 11-beta-hydroxylase. CAH can lead to impaired cortisol production, increased production of androgens, and abnormal genital development in affected individuals.

Another example is lipoid congenital adrenal hyperplasia (LCAH), which is caused by a deficiency in the enzyme steroidogenic acute regulatory protein (StAR). LCAH results in impaired transport of cholesterol into the mitochondria, leading to deficient synthesis of all steroid hormones and accumulation of lipids in the adrenal glands.

Inborn errors of steroid metabolism can be diagnosed through various tests, including blood and urine tests to measure steroid levels and genetic testing to identify mutations in the relevant genes. Treatment typically involves replacement therapy with the deficient hormones or inhibition of excessive hormone production.

Sodium is an essential mineral and electrolyte that is necessary for human health. In a medical context, sodium is often discussed in terms of its concentration in the blood, as measured by serum sodium levels. The normal range for serum sodium is typically between 135 and 145 milliequivalents per liter (mEq/L).

Sodium plays a number of important roles in the body, including:

* Regulating fluid balance: Sodium helps to regulate the amount of water in and around your cells, which is important for maintaining normal blood pressure and preventing dehydration.
* Facilitating nerve impulse transmission: Sodium is involved in the generation and transmission of electrical signals in the nervous system, which is necessary for proper muscle function and coordination.
* Assisting with muscle contraction: Sodium helps to regulate muscle contractions by interacting with other minerals such as calcium and potassium.

Low sodium levels (hyponatremia) can cause symptoms such as confusion, seizures, and coma, while high sodium levels (hypernatremia) can lead to symptoms such as weakness, muscle cramps, and seizures. Both conditions require medical treatment to correct.

Glomerular filtration rate (GFR) is a test used to check how well the kidneys are working. Specifically, it estimates how much blood passes through the glomeruli each minute. The glomeruli are the tiny fibers in the kidneys that filter waste from the blood. A lower GFR number means that the kidneys aren't working properly and may indicate kidney disease.

The GFR is typically calculated using a formula that takes into account the patient's serum creatinine level, age, sex, and race. The most commonly used formula is the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. A normal GFR is usually above 90 mL/min/1.73m2, but this can vary depending on the individual's age and other factors.

Inborn errors of carbohydrate metabolism refer to genetic disorders that affect the body's ability to break down and process carbohydrates, which are sugars and starches that provide energy for the body. These disorders are caused by defects in enzymes or transport proteins that play a critical role in the metabolic pathways involved in carbohydrate metabolism.

There are several types of inborn errors of carbohydrate metabolism, including:

1. Galactosemia: This disorder affects the body's ability to metabolize the sugar galactose, which is found in milk and other dairy products. It is caused by a deficiency of the enzyme galactose-1-phosphate uridylyltransferase.
2. Glycogen storage diseases: These disorders affect the body's ability to store and break down glycogen, which is a complex carbohydrate that serves as a source of energy for the body. There are several types of glycogen storage diseases, each caused by a deficiency in a different enzyme involved in glycogen metabolism.
3. Hereditary fructose intolerance: This disorder affects the body's ability to metabolize the sugar fructose, which is found in fruits and sweeteners. It is caused by a deficiency of the enzyme aldolase B.
4. Pentose phosphate pathway disorders: These disorders affect the body's ability to metabolize certain sugars and generate energy through the pentose phosphate pathway. They are caused by defects in enzymes involved in this pathway.

Symptoms of inborn errors of carbohydrate metabolism can vary widely depending on the specific disorder and its severity. Treatment typically involves dietary restrictions, supplementation with necessary enzymes or cofactors, and management of complications. In some cases, enzyme replacement therapy or even organ transplantation may be considered.

Inborn urea cycle disorders (UCDs) are a group of rare genetic metabolic disorders caused by deficiencies in one of the enzymes or transporters that make up the urea cycle. The urea cycle is a series of biochemical reactions that occur in liver cells, responsible for removing ammonia, a toxic byproduct of protein metabolism, from the bloodstream.

In UCDs, the impaired function of these enzymes or transporters leads to an accumulation of ammonia in the blood (hyperammonemia), which can cause irreversible brain damage and severe neurological symptoms if left untreated. These disorders are usually inherited in an autosomal recessive manner, meaning that an affected individual has two copies of the mutated gene, one from each parent.

There are six main types of UCDs, classified based on the specific enzyme or transporter deficiency:

1. Carbamoyl phosphate synthetase I (CPS1) deficiency
2. Ornithine transcarbamylase (OTC) deficiency
3. Argininosuccinic aciduria (ASA)
4. Citrullinemia type I or II (CTLN1, CTLN2)
5. Arginase deficiency
6. N-acetylglutamate synthetase (NAGS) deficiency

Symptoms of UCDs can vary widely depending on the severity and specific type of the disorder but may include:

* Vomiting
* Lethargy or irritability
* Seizures
* Tremors or seizure-like activity
* Developmental delays or intellectual disability
* Coma

Early diagnosis and treatment are crucial to prevent long-term neurological damage. Treatment options include dietary restrictions, medications that help remove ammonia from the body, and liver transplantation in severe cases. Regular monitoring of blood ammonia levels and other metabolic markers is essential for managing UCDs effectively.

Metabolic brain diseases are a group of disorders caused by genetic defects that affect the body's metabolism and result in abnormal accumulation of harmful substances in the brain. These conditions are present at birth (inborn) or develop during infancy or early childhood. Examples of metabolic brain diseases that are present at birth include:

1. Phenylketonuria (PKU): A disorder caused by a deficiency of the enzyme phenylalanine hydroxylase, which leads to an accumulation of phenylalanine in the brain and can cause intellectual disability, seizures, and behavioral problems if left untreated.
2. Maple syrup urine disease (MSUD): A disorder caused by a deficiency of the enzyme branched-chain ketoacid dehydrogenase, which leads to an accumulation of branched-chain amino acids in the body and can cause intellectual disability, seizures, and metabolic crisis if left untreated.
3. Urea cycle disorders: A group of disorders caused by defects in enzymes that help remove ammonia from the body. Accumulation of ammonia in the blood can lead to brain damage, coma, or death if not treated promptly.
4. Organic acidemias: A group of disorders caused by defects in enzymes that help break down certain amino acids and other organic compounds. These conditions can cause metabolic acidosis, seizures, and developmental delays if left untreated.

Early diagnosis and treatment of these conditions are crucial to prevent irreversible brain damage and other complications. Treatment typically involves dietary restrictions, supplements, and medications to manage the underlying metabolic imbalance. In some cases, enzyme replacement therapy or liver transplantation may be necessary.

Argininosuccinic aciduria (ASA) is a rare inherited metabolic disorder caused by a deficiency of the enzyme argininosuccinate lyase. This enzyme is necessary for the urea cycle, a process that helps rid the body of excess nitrogen produced from protein breakdown. When the urea cycle is not functioning properly, nitrogen accumulates in the form of ammonia, which can be toxic to the brain and other organs.

In ASA, argininosuccinic acid builds up in the blood and urine, giving the condition its name. Symptoms of ASA typically appear within the first few days or weeks of life and may include poor feeding, vomiting, lethargy, seizures, and developmental delay. If left untreated, ASA can lead to serious complications such as intellectual disability, coma, and even death.

Treatment for ASA usually involves a combination of dietary restrictions, medications to reduce ammonia levels, and supplementation with arginine, an amino acid that is not properly metabolized in people with ASA. In some cases, liver transplantation may be necessary. Early diagnosis and treatment are crucial for improving outcomes in individuals with ASA.

Hyperammonemia is a medical condition characterized by an excessively high level of ammonia (a toxic byproduct of protein metabolism) in the blood. This can lead to serious neurological symptoms and complications, as ammonia is highly toxic to the brain. Hyperammonemia can be caused by various underlying conditions, including liver disease, genetic disorders that affect ammonia metabolism, certain medications, and infections. It is important to diagnose and treat hyperammonemia promptly to prevent long-term neurological damage or even death. Treatment typically involves addressing the underlying cause of the condition, as well as providing supportive care such as administering medications that help remove ammonia from the blood.

Axonal transport is the controlled movement of materials and organelles within axons, which are the nerve fibers of neurons (nerve cells). This intracellular transport system is essential for maintaining the structural and functional integrity of axons, particularly in neurons with long axonal processes. There are two types of axonal transport: anterograde transport, which moves materials from the cell body toward the synaptic terminals, and retrograde transport, which transports materials from the synaptic terminals back to the cell body. Anterograde transport is typically slower than retrograde transport and can be divided into fast and slow components based on velocity. Fast anterograde transport moves vesicles containing neurotransmitters and their receptors, as well as mitochondria and other organelles, at speeds of up to 400 mm/day. Slow anterograde transport moves cytoskeletal elements, proteins, and RNA at speeds of 1-10 mm/day. Retrograde transport is primarily responsible for recycling membrane components, removing damaged organelles, and transmitting signals from the axon terminal to the cell body. Dysfunctions in axonal transport have been implicated in various neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Ion transport refers to the active or passive movement of ions, such as sodium (Na+), potassium (K+), chloride (Cl-), and calcium (Ca2+) ions, across cell membranes. This process is essential for various physiological functions, including nerve impulse transmission, muscle contraction, and maintenance of resting membrane potential.

Ion transport can occur through several mechanisms, including:

1. Diffusion: the passive movement of ions down their concentration gradient, from an area of high concentration to an area of low concentration.
2. Facilitated diffusion: the passive movement of ions through specialized channels or transporters in the cell membrane.
3. Active transport: the energy-dependent movement of ions against their concentration gradient, requiring the use of ATP. This process is often mediated by ion pumps, such as the sodium-potassium pump (Na+/K+-ATPase).
4. Co-transport or symport: the coupled transport of two or more different ions or molecules in the same direction, often driven by an electrochemical gradient.
5. Counter-transport or antiport: the coupled transport of two or more different ions or molecules in opposite directions, also often driven by an electrochemical gradient.

Abnormalities in ion transport can lead to various medical conditions, such as cystic fibrosis (which involves defective chloride channel function), hypertension (which may be related to altered sodium transport), and certain forms of heart disease (which can result from abnormal calcium handling).

Membrane transport proteins are specialized biological molecules, specifically integral membrane proteins, that facilitate the movement of various substances across the lipid bilayer of cell membranes. They are responsible for the selective and regulated transport of ions, sugars, amino acids, nucleotides, and other molecules into and out of cells, as well as within different cellular compartments. These proteins can be categorized into two main types: channels and carriers (or pumps). Channels provide a passive transport mechanism, allowing ions or small molecules to move down their electrochemical gradient, while carriers actively transport substances against their concentration gradient, requiring energy usually in the form of ATP. Membrane transport proteins play a crucial role in maintaining cell homeostasis, signaling processes, and many other physiological functions.

Phenylketonurias (PKU) is a genetic disorder characterized by the body's inability to properly metabolize the amino acid phenylalanine, due to a deficiency of the enzyme phenylalanine hydroxylase. This results in a buildup of phenylalanine in the blood and other tissues, which can cause serious neurological problems if left untreated.

The condition is typically detected through newborn screening and can be managed through a strict diet that limits the intake of phenylalanine. If left untreated, PKU can lead to intellectual disability, seizures, behavioral problems, and other serious health issues. In some cases, medication or a liver transplant may also be necessary to manage the condition.

Smith-Lemli-Opitz syndrome (SLOS) is a genetic disorder that affects the development of multiple body systems. It is caused by a deficiency in the enzyme 7-dehydrocholesterol reductase, which is needed for the production of cholesterol in the body.

The symptoms of SLOS can vary widely in severity, but often include developmental delays, intellectual disability, low muscle tone (hypotonia), feeding difficulties, and behavioral problems. Physical abnormalities may also be present, such as cleft palate, heart defects, extra fingers or toes (polydactyly), and genital abnormalities in males.

SLOS is an autosomal recessive disorder, which means that an individual must inherit two copies of the mutated gene (one from each parent) in order to develop the condition. It is typically diagnosed through genetic testing and biochemical analysis of blood or body fluids. Treatment for SLOS may include cholesterol supplementation, special education services, and management of associated medical conditions.

Protein transport, in the context of cellular biology, refers to the process by which proteins are actively moved from one location to another within or between cells. This is a crucial mechanism for maintaining proper cell function and regulation.

Intracellular protein transport involves the movement of proteins within a single cell. Proteins can be transported across membranes (such as the nuclear envelope, endoplasmic reticulum, Golgi apparatus, or plasma membrane) via specialized transport systems like vesicles and transport channels.

Intercellular protein transport refers to the movement of proteins from one cell to another, often facilitated by exocytosis (release of proteins in vesicles) and endocytosis (uptake of extracellular substances via membrane-bound vesicles). This is essential for communication between cells, immune response, and other physiological processes.

It's important to note that any disruption in protein transport can lead to various diseases, including neurological disorders, cancer, and metabolic conditions.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Refractive errors are a group of vision conditions that include nearsightedness (myopia), farsightedness (hyperopia), astigmatism, and presbyopia. These conditions occur when the shape of the eye prevents light from focusing directly on the retina, causing blurred or distorted vision.

Myopia is a condition where distant objects appear blurry while close-up objects are clear. This occurs when the eye is too long or the cornea is too curved, causing light to focus in front of the retina instead of directly on it.

Hyperopia, on the other hand, is a condition where close-up objects appear blurry while distant objects are clear. This happens when the eye is too short or the cornea is not curved enough, causing light to focus behind the retina.

Astigmatism is a condition that causes blurred vision at all distances due to an irregularly shaped cornea or lens.

Presbyopia is a natural aging process that affects everyone as they get older, usually around the age of 40. It causes difficulty focusing on close-up objects and can be corrected with reading glasses, bifocals, or progressive lenses.

Refractive errors can be diagnosed through a comprehensive eye exam and are typically corrected with eyeglasses, contact lenses, or refractive surgery such as LASIK.

A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.

Homogentisate 1,2-dioxygenase (HGD) is an enzyme that plays a crucial role in the catabolism of tyrosine, an aromatic amino acid. This enzyme is involved in the third step of the tyrosine degradation pathway, also known as the tyrosine breakdown or catabolic pathway.

The homogentisate 1,2-dioxygenase enzyme catalyzes the conversion of homogentisic acid (HGA) into maleylacetoacetic acid. This reaction involves the cleavage of the aromatic ring of HGA and the introduction of oxygen, hence the name 'dioxygenase.' The reaction can be summarized as follows:

Homogentisate + O2 → Maleylacetoacetate

Deficiency or dysfunction in homogentisate 1,2-dioxygenase leads to a rare genetic disorder called alkaptonuria. In this condition, the body cannot break down tyrosine properly, resulting in an accumulation of HGA and its oxidation product, alkapton, which can cause damage to connective tissues and joints over time.

Chronic mucocutaneous candidiasis (CMC) is a group of rare disorders characterized by persistent or recurrent Candida infections of the skin, nails, and mucous membranes. The infection can affect various sites such as the mouth, esophagus, respiratory tract, gastrointestinal tract, and genitourinary tract.

CMC is typically caused by an impaired immune response to Candida albicans, a type of fungus that commonly exists on the skin and mucous membranes. In CMC, the immune system fails to control the growth of Candida, leading to chronic or recurrent infections.

The symptoms of CMC can vary depending on the site of infection. Common manifestations include:

* Chronic or recurrent thrush (oral candidiasis)
* Esophagitis (inflammation of the esophagus)
* Chronic nail infections (onychomycosis)
* Skin lesions, such as redness, swelling, and cracks
* Genital infections, including vaginitis and balanitis (inflammation of the head of the penis)

CMC can be associated with other immune disorders, such as endocrine dysfunction, autoimmune diseases, and primary immunodeficiencies. The diagnosis of CMC is based on clinical manifestations, laboratory tests, and imaging studies. Treatment typically involves antifungal medications, such as topical or systemic azoles, echinocandins, or polyenes. In some cases, immunomodulatory therapy may be necessary to manage the underlying immune dysfunction.

Alpha-galactosidase is an enzyme that breaks down complex carbohydrates, specifically those containing alpha-galactose molecules. This enzyme is found in humans, animals, and microorganisms. In humans, a deficiency of this enzyme can lead to a genetic disorder known as Fabry disease, which is characterized by the accumulation of these complex carbohydrates in various tissues and organs, leading to progressive damage. Alpha-galactosidase is also used as a medication for the treatment of Fabry disease, where it is administered intravenously to help break down the accumulated carbohydrates and alleviate symptoms.

Inborn errors of pyruvate metabolism refer to genetic disorders that affect the body's ability to properly metabolize pyruvate, a key intermediate in glucose metabolism. Pyruvate is produced in the cells during the breakdown of glucose for energy production. Normally, pyruvate can be converted into acetyl-CoA and enter the citric acid cycle (also known as the Krebs cycle) for further energy production. However, in individuals with inborn errors of pyruvate metabolism, this conversion process is impaired due to defects in enzymes or transport proteins involved in pyruvate metabolism.

There are several types of inborn errors of pyruvate metabolism, including:

1. Pyruvate dehydrogenase deficiency: This is a genetic disorder caused by mutations in the genes encoding components of the pyruvate dehydrogenase (PDH) complex, which catalyzes the conversion of pyruvate to acetyl-CoA. PDH deficiency can lead to lactic acidosis, neurological problems, and developmental delay.
2. Pyruvate carboxylase deficiency: This is a rare genetic disorder caused by mutations in the gene encoding pyruvate carboxylase, an enzyme that converts pyruvate to oxaloacetate, which can then be used to synthesize glucose. Pyruvate carboxylase deficiency can cause lactic acidosis, seizures, and developmental delay.
3. Mitochondrial disorders: Some mitochondrial disorders can affect pyruvate metabolism by impairing the function of the electron transport chain, which is necessary for energy production in the cells. These disorders can lead to lactic acidosis, muscle weakness, and neurological problems.
4. Other inborn errors: There are several other rare genetic disorders that can affect pyruvate metabolism, including defects in the mitochondrial pyruvate carrier protein, which transports pyruvate into the mitochondria, and deficiencies in enzymes involved in the citric acid cycle.

Treatment for these disorders typically involves managing symptoms, such as controlling lactic acidosis and providing supportive care for neurological problems. In some cases, dietary modifications or supplements may be recommended to help improve pyruvate metabolism.

Homocystinuria is a genetic disorder characterized by the accumulation of homocysteine and its metabolites in the body due to a deficiency in the enzyme cystathionine beta-synthase (CBS). This enzyme is responsible for converting homocysteine to cystathionine, which is a critical step in the metabolic pathway that breaks down methionine.

As a result of this deficiency, homocysteine levels in the blood increase and can lead to various health problems, including neurological impairment, ocular abnormalities (such as ectopia lentis or dislocation of the lens), skeletal abnormalities (such as Marfan-like features), and vascular complications.

Homocystinuria can be diagnosed through newborn screening or by measuring homocysteine levels in the blood or urine. Treatment typically involves a low-methionine diet, supplementation with vitamin B6 (pyridoxine), betaine, and/or methylcobalamin (a form of vitamin B12) to help reduce homocysteine levels and prevent complications associated with the disorder.

Fabry disease is a rare X-linked inherited lysosomal storage disorder caused by mutations in the GLA gene, which encodes the enzyme alpha-galactosidase A. This enzyme deficiency leads to the accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3 or GL-3), in various tissues and organs throughout the body. The accumulation of these lipids results in progressive damage to multiple organ systems, including the heart, kidneys, nerves, and skin.

The symptoms of Fabry disease can vary widely among affected individuals, but common manifestations include:

1. Pain: Acroparesthesias (burning or tingling sensations) in the hands and feet, episodic pain crises, chronic pain, and neuropathy.
2. Skin: Angiokeratomas (small, red, rough bumps on the skin), hypohidrosis (decreased sweating), and anhydrosis (absent sweating).
3. Gastrointestinal: Abdominal pain, diarrhea, constipation, nausea, and vomiting.
4. Cardiovascular: Left ventricular hypertrophy (enlargement of the heart muscle), cardiomyopathy, ischemic heart disease, arrhythmias, and valvular abnormalities.
5. Renal: Proteinuria (protein in the urine), hematuria (blood in the urine), chronic kidney disease, and end-stage renal disease.
6. Nervous system: Hearing loss, tinnitus, vertigo, stroke, and cognitive decline.
7. Ocular: Corneal opacities, cataracts, and retinal vessel abnormalities.
8. Pulmonary: Chronic cough, bronchial hyperresponsiveness, and restrictive lung disease.
9. Reproductive system: Erectile dysfunction in males and menstrual irregularities in females.

Fabry disease affects both males and females, but the severity of symptoms is generally more pronounced in males due to the X-linked inheritance pattern. Early diagnosis and treatment with enzyme replacement therapy (ERT) or chaperone therapy can help manage the progression of the disease and improve quality of life.

The Australian Capital Territory (ACT) is a federal territory of Australia that serves as the country's capital and is home to the city of Canberra. It is not a state, but rather a separate territorial jurisdiction that is self-governing, with its own legislative assembly responsible for local governance.

The ACT was established in 1911 as the site for Australia's capital city, following a compromise between the two largest cities in the country at the time, Sydney and Melbourne, which both sought to be named the national capital. The territory covers an area of approximately 2,358 square kilometers (910 square miles) and has a population of around 430,000 people.

The ACT is home to many important government buildings and institutions, including Parliament House, the High Court of Australia, and the Australian War Memorial. It also boasts a diverse range of natural attractions, such as the Namadgi National Park and the Tidbinbilla Nature Reserve, which offer opportunities for hiking, camping, and wildlife viewing.

In medical terms, the ACT has its own healthcare system and infrastructure, with several hospitals, clinics, and medical centers located throughout the territory. The Australian Government provides funding for public health services in the ACT, while private health insurance is also available to residents. The territory's main hospital, Canberra Hospital, offers a range of specialist medical services, including emergency care, cancer treatment, and mental health services.

Ornithine Carbamoyltransferase (OCT) Deficiency Disease, also known as Ornithine Transcarbamylase Deficiency, is a rare inherited urea cycle disorder. It is caused by a deficiency of the enzyme ornithine carbamoyltransferase, which is responsible for one of the steps in the urea cycle that helps to rid the body of excess nitrogen (in the form of ammonia).

When OCT function is impaired, nitrogen accumulates and forms ammonia, leading to hyperammonemia (elevated blood ammonia levels), which can cause neurological symptoms such as lethargy, vomiting, irritability, and in severe cases, coma or death.

Symptoms of OCT deficiency can range from mild to severe and may include developmental delay, seizures, behavioral changes, and movement disorders. The diagnosis is typically made through newborn screening tests, enzyme assays, and genetic testing. Treatment usually involves a combination of dietary restrictions, medications that help remove nitrogen from the body, and in some cases, liver transplantation.

Argininosuccinic acid is a chemical compound that is an intermediate in the metabolic pathway for the synthesis of arginine, an essential amino acid. This process occurs in the urea cycle, which is responsible for removing excess nitrogen from the body in the form of urea.

In the urea cycle, citrulline reacts with aspartate to form argininosuccinic acid, which is then converted into arginine and fumarate by the enzyme argininosuccinate lyase. Arginine is a semi-essential amino acid that plays important roles in various physiological processes, including protein synthesis, nitric oxide production, and hormone secretion.

Argininosuccinic aciduria is a rare inherited metabolic disorder caused by a deficiency of the enzyme argininosuccinate lyase. This results in an accumulation of argininosuccinic acid in the blood and urine, leading to hyperammonemia (elevated levels of ammonia in the blood), neurological symptoms, and developmental delay. Treatment typically involves a low-protein diet, supplementation with arginine and citrulline, and nitrogen scavenging medications to reduce ammonia levels.

Isovaleryl-CoA Dehydrogenase (IVD) is an enzyme that plays a crucial role in the catabolism of leucine, an essential amino acid. This enzyme is located in the mitochondrial matrix and is responsible for catalyzing the third step in the degradation pathway of leucine.

Specifically, Isovaleryl-CoA Dehydrogenase facilitates the conversion of isovaleryl-CoA to 3-methylcrotonyl-CoA through the removal of two hydrogen atoms from the substrate. This reaction requires the coenzyme flavin adenine dinucleotide (FAD) as an electron acceptor, which gets reduced to FADH2 during the process.

Deficiency in Isovaleryl-CoA Dehydrogenase can lead to a rare genetic disorder known as isovaleric acidemia, characterized by the accumulation of isovaleryl-CoA and its metabolic byproducts, including isovaleric acid, 3-hydroxyisovaleric acid, and methylcrotonylglycine. These metabolites can cause various symptoms such as vomiting, dehydration, metabolic acidosis, seizures, developmental delay, and even coma or death in severe cases.

Monosaccharide transport proteins are a type of membrane transport protein that facilitate the passive or active transport of monosaccharides, such as glucose, fructose, and galactose, across cell membranes. These proteins play a crucial role in the absorption, distribution, and metabolism of carbohydrates in the body.

There are two main types of monosaccharide transport proteins: facilitated diffusion transporters and active transporters. Facilitated diffusion transporters, also known as glucose transporters (GLUTs), passively transport monosaccharides down their concentration gradient without the need for energy. In contrast, active transporters, such as the sodium-glucose cotransporter (SGLT), use energy in the form of ATP to actively transport monosaccharides against their concentration gradient.

Monosaccharide transport proteins are found in various tissues throughout the body, including the intestines, kidneys, liver, and brain. They play a critical role in maintaining glucose homeostasis by regulating the uptake and release of glucose into and out of cells. Dysfunction of these transporters has been implicated in several diseases, such as diabetes, cancer, and neurological disorders.

Hypophosphatasia is a rare inherited metabolic disorder characterized by defective bone mineralization due to deficiency of alkaline phosphatase, an enzyme that is crucial for the formation of strong and healthy bones. This results in skeletal abnormalities, including softening and weakening of the bones (rickets in children and osteomalacia in adults), premature loss of teeth, and an increased risk of fractures.

The disorder can vary widely in severity, from mild cases with few symptoms to severe forms that can lead to disability or even be life-threatening in infancy. Hypophosphatasia is caused by mutations in the ALPL gene, which provides instructions for making the tissue non-specific alkaline phosphatase (TNSALP) enzyme. Inheritance is autosomal recessive, meaning an individual must inherit two copies of the mutated gene (one from each parent) to have the condition.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Diagnostic errors refer to inaccurate or delayed diagnoses of a patient's medical condition, which can lead to improper or unnecessary treatment and potentially serious harm to the patient. These errors can occur due to various factors such as lack of clinical knowledge, failure to consider all possible diagnoses, inadequate communication between healthcare providers and patients, and problems with testing or interpretation of test results. Diagnostic errors are a significant cause of preventable harm in medical care and have been identified as a priority area for quality improvement efforts.

Hydroxocobalamin is a form of vitamin B12 that is used in medical treatments. It is a synthetic version of the naturally occurring compound, and it is often used to treat vitamin B12 deficiencies. Hydroxocobalamin is also used to treat poisoning from cyanide, as it can bind with the cyanide to form a non-toxic compound that can be excreted from the body.

In medical terms, hydroxocobalamin is defined as: "A bright red crystalline compound, C21H30CoN4O7·2H2O, used in the treatment of vitamin B12 deficiency and as an antidote for cyanide poisoning. It is converted in the body to active coenzyme forms."

It's important to note that hydroxocobalamin should only be used under the supervision of a medical professional, as improper use can lead to serious side effects or harm.

Methylmalonic acid (MMA) is an organic compound that is produced in the human body during the metabolism of certain amino acids, including methionine and threonine. It is a type of fatty acid that is intermediate in the breakdown of these amino acids in the liver and other tissues.

Under normal circumstances, MMA is quickly converted to succinic acid, which is then used in the Krebs cycle to generate energy in the form of ATP. However, when there are deficiencies or mutations in enzymes involved in this metabolic pathway, such as methylmalonyl-CoA mutase, MMA can accumulate in the body and cause methylmalonic acidemia, a rare genetic disorder that affects approximately 1 in every 50,000 to 100,000 individuals worldwide.

Elevated levels of MMA in the blood or urine can be indicative of various metabolic disorders, including methylmalonic acidemia, vitamin B12 deficiency, and renal insufficiency. Therefore, measuring MMA levels is often used as a diagnostic tool to help identify and manage these conditions.

Metabolic brain diseases refer to a group of conditions that are caused by disruptions in the body's metabolic processes, which affect the brain. These disorders can be inherited or acquired and can result from problems with the way the body produces, breaks down, or uses energy and nutrients.

Examples of metabolic brain diseases include:

1. Mitochondrial encephalomyopathies: These are a group of genetic disorders that affect the mitochondria, which are the energy-producing structures in cells. When the mitochondria don't function properly, it can lead to muscle weakness, neurological problems, and developmental delays.
2. Leukodystrophies: These are a group of genetic disorders that affect the white matter of the brain, which is made up of nerve fibers covered in myelin, a fatty substance that insulates the fibers and helps them transmit signals. When the myelin breaks down or is not produced properly, it can lead to cognitive decline, motor problems, and other neurological symptoms.
3. Lysosomal storage disorders: These are genetic disorders that affect the lysosomes, which are structures in cells that break down waste products and recycle cellular materials. When the lysosomes don't function properly, it can lead to the accumulation of waste products in cells, including brain cells, causing damage and neurological symptoms.
4. Maple syrup urine disease: This is a genetic disorder that affects the way the body breaks down certain amino acids, leading to a buildup of toxic levels of these substances in the blood and urine. If left untreated, it can cause brain damage, developmental delays, and other neurological problems.
5. Homocystinuria: This is a genetic disorder that affects the way the body processes an amino acid called methionine, leading to a buildup of homocysteine in the blood. High levels of homocysteine can cause damage to the blood vessels and lead to neurological problems, including seizures, developmental delays, and cognitive decline.

Treatment for metabolic brain diseases may involve dietary changes, supplements, medications, or other therapies aimed at managing symptoms and preventing further damage to the brain. In some cases, a stem cell transplant may be recommended as a treatment option.

I am sorry for any confusion, but "Pentanoic Acids" is not a recognized medical term or concept. Pentanoic acid, also known as valeric acid, is an organic compound with the formula CH3CH2CH2CH2CO2H. It is a fatty acid with five carbon atoms, and it may have some uses in industry, but it does not have specific relevance to medical definition or healthcare.

Methylmalonyl-CoA mutase is a mitochondrial enzyme that plays a crucial role in the metabolism of certain amino acids and fatty acids. Specifically, it catalyzes the isomerization of methylmalonyl-CoA to succinyl-CoA, which is an important step in the catabolic pathways of valine, isoleucine, threonine, methionine, odd-chain fatty acids, and cholesterol.

The enzyme requires a cofactor called adenosylcobalamin (vitamin B12) for its activity. In the absence of this cofactor or due to mutations in the gene encoding the enzyme, methylmalonyl-CoA mutase deficiency can occur, leading to the accumulation of methylmalonic acid and other toxic metabolites, which can cause a range of symptoms including vomiting, dehydration, lethargy, hypotonia, developmental delay, and metabolic acidosis. This condition is typically inherited in an autosomal recessive manner and can be diagnosed through biochemical tests and genetic analysis.

Carnitine is a naturally occurring substance in the body that plays a crucial role in energy production. It transports long-chain fatty acids into the mitochondria, where they can be broken down to produce energy. Carnitine is also available as a dietary supplement and is often used to treat or prevent carnitine deficiency.

The medical definition of Carnitine is:

"A quaternary ammonium compound that occurs naturally in animal tissues, especially in muscle, heart, brain, and liver. It is essential for the transport of long-chain fatty acids into the mitochondria, where they can be oxidized to produce energy. Carnitine also functions as an antioxidant and has been studied as a potential treatment for various conditions, including heart disease, diabetes, and kidney disease."

Carnitine is also known as L-carnitine or levocarnitine. It can be found in foods such as red meat, dairy products, fish, poultry, and tempeh. In the body, carnitine is synthesized from the amino acids lysine and methionine with the help of vitamin C and iron. Some people may have a deficiency in carnitine due to genetic factors, malnutrition, or certain medical conditions, such as kidney disease or liver disease. In these cases, supplementation may be necessary to prevent or treat symptoms of carnitine deficiency.

Oxidoreductases acting on CH-CH group donors are a class of enzymes within the larger group of oxidoreductases, which are responsible for catalyzing oxidation-reduction reactions. Specifically, this subclass of enzymes acts upon donors containing a carbon-carbon (CH-CH) bond, where one atom or group of atoms is oxidized and another is reduced during the reaction process. These enzymes play crucial roles in various metabolic pathways, including the breakdown and synthesis of carbohydrates, lipids, and amino acids.

The reactions catalyzed by these enzymes involve the transfer of electrons and hydrogen atoms between the donor and an acceptor molecule. This process often results in the formation or cleavage of carbon-carbon bonds, making them essential for numerous biological processes. The systematic name for this class of enzymes is typically structured as "donor:acceptor oxidoreductase," where donor and acceptor represent the molecules involved in the electron transfer process.

Examples of enzymes that fall under this category include:

1. Aldehyde dehydrogenases (EC 1.2.1.3): These enzymes catalyze the oxidation of aldehydes to carboxylic acids, using NAD+ as an electron acceptor.
2. Dihydrodiol dehydrogenase (EC 1.3.1.14): This enzyme is responsible for the oxidation of dihydrodiols to catechols in the biodegradation of aromatic compounds.
3. Succinate dehydrogenase (EC 1.3.5.1): A key enzyme in the citric acid cycle, succinate dehydrogenase catalyzes the oxidation of succinate to fumarate and reduces FAD to FADH2.
4. Xylose reductase (EC 1.1.1.307): This enzyme is involved in the metabolism of pentoses, where it reduces xylose to xylitol using NADPH as a cofactor.

The Electron Transport Chain (ETC) is a series of complexes in the inner mitochondrial membrane that are involved in the process of cellular respiration. It is the final pathway for electrons derived from the oxidation of nutrients such as glucose, fatty acids, and amino acids to be transferred to molecular oxygen. This transfer of electrons drives the generation of a proton gradient across the inner mitochondrial membrane, which is then used by ATP synthase to produce ATP, the main energy currency of the cell.

The electron transport chain consists of four complexes (I-IV) and two mobile electron carriers (ubiquinone and cytochrome c). Electrons from NADH and FADH2 are transferred to Complex I and Complex II respectively, which then pass them along to ubiquinone. Ubiquinone then transfers the electrons to Complex III, which passes them on to cytochrome c. Finally, cytochrome c transfers the electrons to Complex IV, where they combine with oxygen and protons to form water.

The transfer of electrons through the ETC is accompanied by the pumping of protons from the mitochondrial matrix to the intermembrane space, creating a proton gradient. The flow of protons back across the inner membrane through ATP synthase drives the synthesis of ATP from ADP and inorganic phosphate.

Overall, the electron transport chain is a crucial process for generating energy in the form of ATP in the cell, and it plays a key role in many metabolic pathways.

Inborn errors of fructose metabolism refer to genetic disorders that affect the body's ability to break down and process fructose, a simple sugar found in fruits, vegetables, and honey. These disorders are caused by mutations in genes responsible for encoding enzymes involved in fructose metabolism.

The two main types of inborn errors of fructose metabolism are:

1. Hereditary Fructose Intolerance (HFI): This is a rare genetic disorder caused by a deficiency of the enzyme aldolase B, which is necessary for the breakdown of fructose in the liver. When individuals with HFI consume fructose or sucrose (a disaccharide that contains fructose and glucose), they experience a buildup of toxic metabolites, leading to symptoms such as vomiting, abdominal pain, hypoglycemia, and in severe cases, liver damage and failure.
2. Fructose-1,6-bisphosphatase Deficiency (FBPase Deficiency): This is a rare autosomal recessive disorder caused by a deficiency of the enzyme fructose-1,6-bisphosphatase, which is essential for gluconeogenesis (the process of generating glucose from non-carbohydrate sources). Individuals with FBPase Deficiency experience symptoms such as hypoglycemia, lactic acidosis, and hyperventilation, particularly during periods of fasting or illness.

Both disorders can be managed through dietary restrictions and close monitoring of blood sugar levels. In severe cases, enzyme replacement therapy or liver transplantation may be considered.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

Glutarates are compounds that contain a glutaric acid group. Glutaric acid is a carboxylic acid with a five-carbon chain and two carboxyl groups at the 1st and 5th carbon positions. Glutarates can be found in various substances, including certain foods and medications.

In a medical context, glutarates are sometimes used as ingredients in pharmaceutical products. For example, sodium phenylbutyrate, which is a salt of phenylbutyric acid and butyric acid, contains a glutaric acid group and is used as a medication to treat urea cycle disorders.

Glutarates can also be found in some metabolic pathways in the body, where they play a role in energy production and other biochemical processes. However, abnormal accumulation of glutaric acid or its derivatives can lead to certain medical conditions, such as glutaric acidemia type I, which is an inherited disorder of metabolism that can cause neurological symptoms and other health problems.

Maple Syrup Urine Disease (MSUD) is a rare inherited metabolic disorder characterized by an inability to break down certain amino acids (leucine, isoleucine, and valine) due to deficiency of the enzyme complex branched-chain keto acid dehydrogenase. This results in their accumulation in body fluids, including urine, which gives it a characteristic sweet smell, reminiscent of maple syrup.

The disease can lead to serious neurological complications if left untreated, including seizures, vomiting, mental retardation, and even death. There are different forms of MSUD, ranging from severe (classic) to milder (intermittent or variant). Treatment typically involves a strict lifelong diet low in these amino acids, regular monitoring of blood and urine, and sometimes supplementation with enzymes or medications.

Erythropoietic Porphyria (EP) is a rare inherited disorder of the heme biosynthesis pathway, specifically caused by a deficiency of the enzyme uroporphyrinogen III synthase. This results in the accumulation of porphyrin precursors, particularly uroporphyrin I and coproporphyrin I, in erythrocytes (red blood cells), bone marrow, and other tissues. The accumulation of these porphyrins leads to photosensitivity, hemolysis, and iron overload.

The symptoms of EP typically appear in childhood or early adulthood and include severe skin fragility and blistering, particularly on sun-exposed areas, which can result in scarring, disfigurement, and increased susceptibility to infection. Other features may include anemia due to hemolysis, iron overload, and splenomegaly (enlarged spleen).

The diagnosis of EP is based on clinical symptoms, laboratory tests measuring porphyrin levels in blood and urine, and genetic testing to confirm the presence of pathogenic variants in the UROS gene. Treatment for EP includes avoidance of sunlight exposure, use of sun-protective measures, and management of anemia with blood transfusions or erythropoietin injections. In some cases, bone marrow transplantation may be considered as a curative treatment option.

Biological models, also known as physiological models or organismal models, are simplified representations of biological systems, processes, or mechanisms that are used to understand and explain the underlying principles and relationships. These models can be theoretical (conceptual or mathematical) or physical (such as anatomical models, cell cultures, or animal models). They are widely used in biomedical research to study various phenomena, including disease pathophysiology, drug action, and therapeutic interventions.

Examples of biological models include:

1. Mathematical models: These use mathematical equations and formulas to describe complex biological systems or processes, such as population dynamics, metabolic pathways, or gene regulation networks. They can help predict the behavior of these systems under different conditions and test hypotheses about their underlying mechanisms.
2. Cell cultures: These are collections of cells grown in a controlled environment, typically in a laboratory dish or flask. They can be used to study cellular processes, such as signal transduction, gene expression, or metabolism, and to test the effects of drugs or other treatments on these processes.
3. Animal models: These are living organisms, usually vertebrates like mice, rats, or non-human primates, that are used to study various aspects of human biology and disease. They can provide valuable insights into the pathophysiology of diseases, the mechanisms of drug action, and the safety and efficacy of new therapies.
4. Anatomical models: These are physical representations of biological structures or systems, such as plastic models of organs or tissues, that can be used for educational purposes or to plan surgical procedures. They can also serve as a basis for developing more sophisticated models, such as computer simulations or 3D-printed replicas.

Overall, biological models play a crucial role in advancing our understanding of biology and medicine, helping to identify new targets for therapeutic intervention, develop novel drugs and treatments, and improve human health.

Glutaryl-CoA Dehydrogenase (GCDH) is an enzyme that plays a crucial role in the catabolism of the amino acids lysine and hydroxylysine. It is located in the inner mitochondrial membrane and functions as a homotetramer, with each subunit containing one molecule of FAD as a cofactor.

GCDH catalyzes the oxidative decarboxylation of glutaryl-CoA to form succinyl-CoA, which is then further metabolized in the citric acid cycle. This reaction also involves the reduction of FAD to FADH2, which can subsequently be used in the electron transport chain to generate ATP.

Deficiency in GCDH function can lead to a rare inherited disorder called glutaric acidemia type I (GA-I), which is characterized by an accumulation of glutaryl-CoA and its metabolites, including glutaric acid and 3-hydroxyglutaric acid. These metabolites can cause neurological damage and intellectual disability if left untreated.

Amidinotransferases are a group of enzymes that play a role in the metabolism of amino acids and other biologically active compounds. These enzymes catalyze the transfer of an amidino group (-NH-C=NH) from one molecule to another, typically from an amino acid or related compound donor to an acceptor molecule.

The amidinotransferases are classified as a subgroup of the larger family of enzymes known as transferases, which catalyze the transfer of various functional groups between molecules. Within this family, the amidinotransferases are further divided into several subfamilies based on their specific functions and the types of donor and acceptor molecules they act upon.

One example of an amidinotransferase is arginine:glycine amidinotransferase (AGAT), which plays a role in the biosynthesis of creatine, a compound that is important for energy metabolism in muscles and other tissues. AGAT transfers an amidino group from arginine to glycine, forming guanidinoacetate and ornithine as products.

Abnormalities in the activity of amidinotransferases have been implicated in various diseases, including neurological disorders and certain genetic conditions. For example, mutations in the gene encoding AGAT have been associated with a rare inherited disorder called cerebral creatine deficiency syndrome type 1 (CCDS1), which is characterized by developmental delay, intellectual disability, and other neurological symptoms.

Inborn errors of metal metabolism refer to genetic disorders that affect the way the body processes and handles certain metallic elements. These disorders can result in an accumulation or deficiency of specific metals, leading to various clinical manifestations. Examples of such conditions include:

1. Wilson's disease: An autosomal recessive disorder caused by a mutation in the ATP7B gene, which results in abnormal copper metabolism and accumulation in various organs, particularly the liver and brain.
2. Menkes disease: An X-linked recessive disorder caused by a mutation in the ATP7A gene, leading to impaired copper transport and deficiency, affecting the brain, bones, and connective tissue.
3. Hemochromatosis: An autosomal recessive disorder characterized by excessive iron absorption and deposition in various organs, causing damage to the liver, heart, and pancreas.
4. Acrodermatitis enteropathica: A rare autosomal recessive disorder caused by a mutation in the SLC39A4 gene, resulting in zinc deficiency and affecting the skin, gastrointestinal system, and immune function.
5. Disturbances in manganese metabolism: Rare genetic disorders that can lead to either manganese accumulation or deficiency, causing neurological symptoms.

These conditions often require specialized medical management, including dietary modifications, chelation therapy, and/or supplementation to maintain appropriate metal homeostasis and prevent organ damage.

Carrier proteins, also known as transport proteins, are a type of protein that facilitates the movement of molecules across cell membranes. They are responsible for the selective and active transport of ions, sugars, amino acids, and other molecules from one side of the membrane to the other, against their concentration gradient. This process requires energy, usually in the form of ATP (adenosine triphosphate).

Carrier proteins have a specific binding site for the molecule they transport, and undergo conformational changes upon binding, which allows them to move the molecule across the membrane. Once the molecule has been transported, the carrier protein returns to its original conformation, ready to bind and transport another molecule.

Carrier proteins play a crucial role in maintaining the balance of ions and other molecules inside and outside of cells, and are essential for many physiological processes, including nerve impulse transmission, muscle contraction, and nutrient uptake.

"Failure to Thrive" is a medical term used to describe a condition in infants and children who are not growing and gaining weight as expected. It is typically defined as significant deviation from normal growth patterns, such as poor weight gain or loss, slow increase in length/height, and delayed developmental milestones. The condition can have various causes, including medical, psychological, social, and environmental factors. Early identification and intervention are crucial to address the underlying cause and promote healthy growth and development.

Hyperargininemia is a rare genetic disorder characterized by an excess of arginine in the blood. Arginine is an amino acid, which are the building blocks of proteins. In hyperargininemia, there is a deficiency or dysfunction of the enzyme argininosuccinate synthetase, leading to an accumulation of arginine and related compounds in the body. This can cause various symptoms such as intellectual disability, seizures, spasticity, and feeding difficulties. It is inherited in an autosomal recessive manner, meaning that an individual must receive two copies of the defective gene (one from each parent) to develop the condition.

Long-chain-3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) is a mitochondrial enzyme that plays a crucial role in the beta-oxidation of fatty acids. Specifically, LCHAD catalyzes the third step of this process by oxidizing long-chain 3-hydroxyacyl-CoA molecules to 3-ketoacyl-CoAs, using NAD+ as an electron acceptor. This reaction is essential for generating energy in the form of ATP and reducing equivalents (NADH and FADH2) through the citric acid cycle.

Deficiencies in LCHAD can lead to a rare autosomal recessive disorder known as long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD). This condition impairs the body's ability to metabolize long-chain fatty acids, particularly during periods of fasting or increased energy demands. Symptoms can include hypoketotic hypoglycemia, muscle weakness, cardiomyopathy, and retinal damage, among others. Early diagnosis and management are crucial for improving outcomes in affected individuals.

Transport vesicles are membrane-bound sacs or containers within cells that are responsible for the intracellular transport of proteins, lipids, and other cargo. These vesicles form when a portion of a donor membrane buds off, enclosing the cargo inside. There are different types of transport vesicles, including:

1. Endoplasmic reticulum (ER) vesicles: These vesicles form from the ER and transport proteins to the Golgi apparatus for further processing.
2. Golgi-derived vesicles: After proteins have been processed in the Golgi, they are packaged into transport vesicles that can deliver them to their final destinations within the cell or to the plasma membrane for secretion.
3. Endocytic vesicles: These vesicles form when a portion of the plasma membrane invaginates and pinches off, engulfing extracellular material or fluid. Examples include clathrin-coated vesicles and caveolae.
4. Lysosomal vesicles: These vesicles transport materials to lysosomes for degradation.
5. Secretory vesicles: These vesicles store proteins and other molecules that will be secreted from the cell. When stimulated, these vesicles fuse with the plasma membrane, releasing their contents to the extracellular space.

Alkaptonuria is a rare inherited metabolic disorder characterized by the accumulation of homogentisic acid in various tissues and body fluids due to a deficiency in the enzyme homogentisate 1,2-dioxygenase. This enzyme deficiency leads to an inability to break down tyrosine and phenylalanine amino acids properly, causing their byproduct, homogentisic acid, to build up in the body.

The accumulation of homogentisic acid can result in several clinical manifestations:

1. Dark urine: Homogentisic acid oxidizes and turns dark brown or black when exposed to air, giving the condition its name "alkaptonuria," derived from Greek words 'alos' (meaning 'strange') and 'kapto' (meaning 'I become black').
2. Arthritis: Over time, homogentisic acid deposits in connective tissues, particularly cartilage, causing damage and leading to a form of arthritis called ochronosis. This can result in stiffness, pain, and limited mobility in affected joints.
3. Heart problems: Homogentisic acid accumulation in heart valves may lead to thickening and calcification, potentially resulting in heart disease and valve dysfunction.
4. Kidney stones: The accumulation of homogentisic acid can form kidney stones, which can cause pain and potential kidney damage if they become lodged in the urinary tract.

There is no cure for alkaptonuria; however, treatment aims to manage symptoms and slow disease progression. A low-protein diet may help reduce tyrosine and phenylalanine intake, while increased hydration can help prevent kidney stone formation. Nitisinone, a medication that inhibits the production of homogentisic acid, has shown promise in managing alkaptonuria symptoms. Regular monitoring and early intervention are crucial to minimize complications associated with this rare condition.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

A rare disease, also known as an orphan disease, is a health condition that affects fewer than 200,000 people in the United States or fewer than 1 in 2,000 people in Europe. There are over 7,000 rare diseases identified, and many of them are severe, chronic, and often life-threatening. The causes of rare diseases can be genetic, infectious, environmental, or degenerative. Due to their rarity, research on rare diseases is often underfunded, and treatments may not be available or well-studied. Additionally, the diagnosis of rare diseases can be challenging due to a lack of awareness and understanding among healthcare professionals.

Citrullinemia is a rare inherited metabolic disorder characterized by the body's inability to properly process and eliminate certain toxic byproducts that are generated during the breakdown of proteins. This condition results from a deficiency of the enzyme argininosuccinate synthetase, which is required for the normal functioning of the urea cycle. The urea cycle is a series of biochemical reactions that occur in the liver and help to convert ammonia, a toxic substance, into urea, which can then be excreted by the kidneys.

There are two main types of citrullinemia: type I (also known as classic citrullinemia) and type II (also known as citrullinemia type II or adult-onset citrullinemia). Type I is typically more severe and can present in newborns with symptoms such as poor feeding, vomiting, seizures, and developmental delays. If left untreated, it can lead to serious complications, including intellectual disability, coma, and even death.

Type II citrullinemia, on the other hand, tends to present later in life, often in adulthood, and may cause symptoms such as confusion, seizures, and neurological problems. It is important to note that some individuals with type II citrullinemia may never develop any symptoms at all.

Treatment for citrullinemia typically involves a combination of dietary restrictions, supplements, and medications to help manage the buildup of toxic byproducts in the body. In severe cases, liver transplantation may be considered as a last resort.

Multiple Acyl Coenzyme A Dehydrogenase Deficiency (MADD) is a rare inherited metabolic disorder that affects the body's ability to break down certain fats and proteins. It is caused by mutations in genes that code for enzymes involved in the electron transfer flavoprotein-ubiquinone (ETF-QO) complex, which is responsible for transferring electrons from various acyl-CoA dehydrogenases to the electron transport chain during fatty acid and amino acid oxidation.

As a result of these genetic defects, there is a buildup of unoxidized acyl-CoA molecules in the body, leading to the accumulation of toxic intermediates that can damage organs and tissues. This can cause a wide range of symptoms, including hypoglycemia, metabolic acidosis, cardiac arrhythmias, muscle weakness, and developmental delays.

MADD is typically classified into three types based on the age of onset and severity of symptoms: neonatal, infantile, and late-onset. The neonatal form is the most severe and often leads to death in early infancy, while the infantile and late-onset forms can present with milder symptoms that may not become apparent until later in life.

Treatment for MADD typically involves a combination of dietary modifications, such as restricting long-chain fatty acids and supplementing with medium-chain triglycerides, and oral supplementation with riboflavin (vitamin B2), which has been shown to improve the activity of the ETF-QO complex in some cases.

Amino acids are organic compounds that serve as the building blocks of proteins. They consist of a central carbon atom, also known as the alpha carbon, which is bonded to an amino group (-NH2), a carboxyl group (-COOH), a hydrogen atom (H), and a variable side chain (R group). The R group can be composed of various combinations of atoms such as hydrogen, oxygen, sulfur, nitrogen, and carbon, which determine the unique properties of each amino acid.

There are 20 standard amino acids that are encoded by the genetic code and incorporated into proteins during translation. These include:

1. Alanine (Ala)
2. Arginine (Arg)
3. Asparagine (Asn)
4. Aspartic acid (Asp)
5. Cysteine (Cys)
6. Glutamine (Gln)
7. Glutamic acid (Glu)
8. Glycine (Gly)
9. Histidine (His)
10. Isoleucine (Ile)
11. Leucine (Leu)
12. Lysine (Lys)
13. Methionine (Met)
14. Phenylalanine (Phe)
15. Proline (Pro)
16. Serine (Ser)
17. Threonine (Thr)
18. Tryptophan (Trp)
19. Tyrosine (Tyr)
20. Valine (Val)

Additionally, there are several non-standard or modified amino acids that can be incorporated into proteins through post-translational modifications, such as hydroxylation, methylation, and phosphorylation. These modifications expand the functional diversity of proteins and play crucial roles in various cellular processes.

Amino acids are essential for numerous biological functions, including protein synthesis, enzyme catalysis, neurotransmitter production, energy metabolism, and immune response regulation. Some amino acids can be synthesized by the human body (non-essential), while others must be obtained through dietary sources (essential).

A cell membrane, also known as the plasma membrane, is a thin semi-permeable phospholipid bilayer that surrounds all cells in animals, plants, and microorganisms. It functions as a barrier to control the movement of substances in and out of the cell, allowing necessary molecules such as nutrients, oxygen, and signaling molecules to enter while keeping out harmful substances and waste products. The cell membrane is composed mainly of phospholipids, which have hydrophilic (water-loving) heads and hydrophobic (water-fearing) tails. This unique structure allows the membrane to be flexible and fluid, yet selectively permeable. Additionally, various proteins are embedded in the membrane that serve as channels, pumps, receptors, and enzymes, contributing to the cell's overall functionality and communication with its environment.

Metabolic diseases are a group of disorders caused by abnormal chemical reactions in your body's cells. These reactions are part of a complex process called metabolism, where your body converts the food you eat into energy.

There are several types of metabolic diseases, but they most commonly result from:

1. Your body not producing enough of certain enzymes that are needed to convert food into energy.
2. Your body producing too much of certain substances or toxins, often due to a genetic disorder.

Examples of metabolic diseases include phenylketonuria (PKU), diabetes, and gout. PKU is a rare condition where the body cannot break down an amino acid called phenylalanine, which can lead to serious health problems if left untreated. Diabetes is a common disorder that occurs when your body doesn't produce enough insulin or can't properly use the insulin it produces, leading to high blood sugar levels. Gout is a type of arthritis that results from too much uric acid in the body, which can form crystals in the joints and cause pain and inflammation.

Metabolic diseases can be inherited or acquired through environmental factors such as diet or lifestyle choices. Many metabolic diseases can be managed with proper medical care, including medication, dietary changes, and lifestyle modifications.

Mucopolysaccharidoses (MPS) are a group of inherited metabolic disorders caused by the deficiency of specific enzymes needed to break down complex sugars called glycosaminoglycans (GAGs or mucopolysaccharides). As a result, these GAGs accumulate in various tissues and organs, leading to progressive cellular damage and multi-organ dysfunction. There are several types of MPS, including Hurler syndrome, Hunter syndrome, Sanfilippo syndrome, Morquio syndrome, Maroteaux-Lamy syndrome, and Sly syndrome, each resulting from a deficiency in one of the eleven different enzymes involved in GAGs metabolism. The clinical presentation, severity, and prognosis vary among the types but commonly include features such as developmental delay, coarse facial features, skeletal abnormalities, hearing loss, heart problems, and reduced life expectancy.

Iron metabolism disorders are a group of medical conditions that affect the body's ability to absorb, transport, store, or utilize iron properly. Iron is an essential nutrient that plays a crucial role in various bodily functions, including oxygen transportation and energy production. However, imbalances in iron levels can lead to several health issues.

There are two main types of iron metabolism disorders:

1. Iron deficiency anemia (IDA): This condition occurs when the body lacks adequate iron to produce sufficient amounts of hemoglobin, a protein in red blood cells responsible for carrying oxygen throughout the body. Causes of IDA may include inadequate dietary iron intake, blood loss, or impaired iron absorption due to conditions like celiac disease or inflammatory bowel disease.
2. Hemochromatosis: This is a genetic disorder characterized by excessive absorption and accumulation of iron in various organs, including the liver, heart, and pancreas. Over time, this excess iron can lead to organ damage and diseases such as cirrhosis, heart failure, diabetes, and arthritis. Hemochromatosis is typically caused by mutations in the HFE gene, which regulates iron absorption in the intestines.

Other iron metabolism disorders include:

* Anemia of chronic disease (ACD): A type of anemia that occurs in individuals with chronic inflammation or infection, where iron is not efficiently used for hemoglobin production due to altered regulation.
* Sideroblastic anemias: These are rare disorders characterized by the abnormal formation of ringed sideroblasts (immature red blood cells containing iron-laden mitochondria) in the bone marrow, leading to anemia and other symptoms.
* Iron-refractory iron deficiency anemia (IRIDA): A rare inherited disorder caused by mutations in the TMPRSS6 gene, resulting in impaired regulation of hepcidin, a hormone that controls iron absorption and distribution in the body. This leads to both iron deficiency and iron overload.

Proper diagnosis and management of iron metabolism disorders are essential to prevent complications and maintain overall health. Treatment options may include dietary modifications, iron supplementation, phlebotomy (bloodletting), or chelation therapy, depending on the specific disorder and its severity.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

Lysosomal storage diseases (LSDs) are a group of rare inherited metabolic disorders caused by defects in lysosomal function. Lysosomes are membrane-bound organelles within cells that contain enzymes responsible for breaking down and recycling various biomolecules, such as proteins, lipids, and carbohydrates. In LSDs, the absence or deficiency of specific lysosomal enzymes leads to the accumulation of undigested substrates within the lysosomes, resulting in cellular dysfunction and organ damage.

These disorders can affect various organs and systems in the body, including the brain, nervous system, bones, skin, and visceral organs. Symptoms may include developmental delays, neurological impairment, motor dysfunction, bone abnormalities, coarse facial features, hepatosplenomegaly (enlarged liver and spleen), and recurrent infections.

Examples of LSDs include Gaucher disease, Tay-Sachs disease, Niemann-Pick disease, Fabry disease, Pompe disease, and mucopolysaccharidoses (MPS). Treatment options for LSDs may include enzyme replacement therapy, substrate reduction therapy, or bone marrow transplantation. Early diagnosis and intervention can help improve the prognosis and quality of life for affected individuals.

Pyruvate Dehydrogenase Complex (PDH) Deficiency is a genetic disorder that affects the body's ability to convert certain food molecules into energy. The pyruvate dehydrogenase complex is a group of enzymes that converts pyruvate, a byproduct of glucose metabolism in the cell's cytoplasm, into acetyl-CoA, which then enters the citric acid cycle (also known as the Krebs cycle) in the mitochondria to produce energy in the form of ATP.

PDH deficiency results from mutations in one or more genes encoding the subunits of the PDH complex or its activators, leading to reduced enzymatic activity. This impairs the conversion of pyruvate to acetyl-CoA and causes an accumulation of pyruvate in body tissues and fluids, particularly during periods of metabolic stress such as illness, infection, or fasting.

The severity of PDH deficiency can vary widely, from mild to severe forms, depending on the extent of enzyme dysfunction. Symptoms may include developmental delay, hypotonia (low muscle tone), seizures, poor feeding, and metabolic acidosis. In severe cases, it can lead to neurological damage, lactic acidosis, and early death if not diagnosed and treated promptly.

PDH deficiency is typically diagnosed through biochemical tests that measure the activity of the PDH complex in cultured skin fibroblasts or muscle tissue. Genetic testing may also be used to identify specific gene mutations causing the disorder. Treatment usually involves a low-carbohydrate, high-fat diet and supplementation with thiamine (vitamin B1), which is an essential cofactor for PDH complex activity. In some cases, dialysis or other supportive measures may be necessary to manage metabolic acidosis and other complications.

Adenylosuccinate Lyase is a crucial enzyme in the purine nucleotide biosynthesis pathway. Its primary function is to catalyze the conversion of adenylosuccinate into adenosine monophosphate (AMP) and fumarate in two consecutive steps. This enzyme plays an essential role in the metabolism of purines, which are vital components of DNA, RNA, and energy transfer molecules like ATP. Deficiency in this enzyme can lead to a rare genetic disorder known as Adenylosuccinase Deficiency or Adenylosuccinate Lyase Deficiency, characterized by neurological symptoms, developmental delays, and physical disabilities.

Neuroaxonal dystrophies (NADs) are a group of inherited neurological disorders characterized by degeneration of the neuronal axons, which are the long extensions of nerve cells that transmit impulses to other cells. This degeneration leads to progressive loss of motor and cognitive functions.

The term "neuroaxonal dystrophy" refers to a specific pattern of abnormalities seen on electron microscopy in nerve cells, including accumulation of membranous structures called "spheroids" or "tubulovesicular structures" within the axons.

NADs can be caused by mutations in various genes that play a role in maintaining the structure and function of neuronal axons. The most common forms of NADs include Infantile Neuroaxonal Dystrophy (INAD) or Seitelberger's Disease, and Late-Onset Neuroaxonal Dystrophy (LONAD).

Symptoms of INAD typically begin between ages 6 months and 2 years, and may include muscle weakness, hypotonia, decreased reflexes, vision loss, hearing impairment, and developmental delay. LONAD usually presents in childhood or adolescence with symptoms such as ataxia, dysarthria, cognitive decline, and behavioral changes.

Currently, there is no cure for NADs, and treatment is focused on managing symptoms and improving quality of life.

Ornithine-oxo-acid transaminase (OAT), also known as ornithine aminotransferase, is a urea cycle enzyme that catalyzes the reversible transfer of an amino group from ornithine to α-ketoglutarate, producing glutamate semialdehyde and glutamate. This reaction is an essential part of the urea cycle, which is responsible for the detoxification of ammonia in the body. Deficiencies in OAT can lead to a genetic disorder called ornithine transcarbamylase deficiency (OTCD), which can cause hyperammonemia and neurological symptoms.

Inborn genetic diseases, also known as inherited genetic disorders, are conditions caused by abnormalities in an individual's DNA that are present at conception. These abnormalities can include mutations, deletions, or rearrangements of genes or chromosomes. In many cases, these genetic changes are inherited from one or both parents and may be passed down through families.

Inborn genetic diseases can affect any part of the body and can cause a wide range of symptoms, which can vary in severity depending on the specific disorder. Some genetic disorders are caused by mutations in a single gene, while others are caused by changes in multiple genes or chromosomes. In some cases, environmental factors may also contribute to the development of these conditions.

Examples of inborn genetic diseases include cystic fibrosis, sickle cell anemia, Huntington's disease, Duchenne muscular dystrophy, and Down syndrome. These conditions can have significant impacts on an individual's health and quality of life, and many require ongoing medical management and treatment. In some cases, genetic counseling and testing may be recommended for individuals with a family history of a particular genetic disorder to help them make informed decisions about their reproductive options.

Anion transport proteins are specialized membrane transport proteins that facilitate the movement of negatively charged ions, known as anions, across biological membranes. These proteins play a crucial role in maintaining ionic balance and regulating various physiological processes within the body.

There are several types of anion transport proteins, including:

1. Cl-/HCO3- exchangers (also known as anion exchangers or band 3 proteins): These transporters facilitate the exchange of chloride (Cl-) and bicarbonate (HCO3-) ions across the membrane. They are widely expressed in various tissues, including the red blood cells, gastrointestinal tract, and kidneys, where they help regulate pH, fluid balance, and electrolyte homeostasis.
2. Sulfate permeases: These transporters facilitate the movement of sulfate ions (SO42-) across membranes. They are primarily found in the epithelial cells of the kidneys, intestines, and choroid plexus, where they play a role in sulfur metabolism and absorption.
3. Cl- channels: These proteins form ion channels that allow chloride ions to pass through the membrane. They are involved in various physiological processes, such as neuronal excitability, transepithelial fluid transport, and cell volume regulation.
4. Cation-chloride cotransporters: These transporters move both cations (positively charged ions) and chloride anions together across the membrane. They are involved in regulating neuronal excitability, cell volume, and ionic balance in various tissues.

Dysfunction of anion transport proteins has been implicated in several diseases, such as cystic fibrosis (due to mutations in the CFTR Cl- channel), distal renal tubular acidosis (due to defects in Cl-/HCO3- exchangers), and some forms of epilepsy (due to abnormalities in cation-chloride cotransporters).

Acyl-CoA dehydrogenase is a group of enzymes that play a crucial role in the body's energy production process. Specifically, they are involved in the breakdown of fatty acids within the cells.

More technically, acyl-CoA dehydrogenases catalyze the removal of electrons from the thiol group of acyl-CoAs, forming a trans-double bond and generating FADH2. This reaction is the first step in each cycle of fatty acid beta-oxidation, which occurs in the mitochondria of cells.

There are several different types of acyl-CoA dehydrogenases, each specific to breaking down different lengths of fatty acids. For example, very long-chain acyl-CoA dehydrogenase (VLCAD) is responsible for breaking down longer chain fatty acids, while medium-chain acyl-CoA dehydrogenase (MCAD) breaks down medium-length chains.

Deficiencies in these enzymes can lead to various metabolic disorders, such as MCAD deficiency or LC-FAOD (long-chain fatty acid oxidation disorders), which can cause symptoms like vomiting, lethargy, and muscle weakness, especially during periods of fasting or illness.

Primary hyperoxaluria is a rare genetic disorder characterized by overproduction of oxalate in the body due to mutations in specific enzymes involved in oxalate metabolism. There are three types of primary hyperoxaluria (PH1, PH2, and PH3), with PH1 being the most common and severe form.

In primary hyperoxaluria type 1 (PH1), there is a deficiency or dysfunction in the enzyme alanine-glyoxylate aminotransferase (AGT), which leads to an accumulation of glyoxylate. Glyoxylate is then converted to oxalate, resulting in increased oxalate production. Oxalate is a compound that naturally occurs in the body but is primarily excreted through the kidneys. When there is an overproduction of oxalate, it can lead to the formation of calcium oxalate crystals in various tissues, including the kidneys. This can cause recurrent kidney stones, nephrocalcinosis (calcium deposits in the kidneys), and eventually chronic kidney disease or end-stage renal failure.

Primary hyperoxaluria type 2 (PH2) is caused by a deficiency or dysfunction in the enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR), leading to an accumulation of glyoxylate, which is subsequently converted to oxalate. PH2 has a milder clinical presentation compared to PH1.

Primary hyperoxaluria type 3 (PH3) is a rare form caused by mutations in the gene HOGA1, which encodes for 4-hydroxy-2-oxoglutarate aldolase. This enzyme deficiency results in an increase in glyoxylate and, subsequently, oxalate production.

Early diagnosis and management of primary hyperoxaluria are crucial to prevent or slow down the progression of kidney damage. Treatment options include increased fluid intake, medications to reduce stone formation (such as potassium citrate), and in some cases, liver-kidney transplantation.

Cation transport proteins are a type of membrane protein that facilitate the movement of cations (positively charged ions) across biological membranes. These proteins play a crucial role in maintaining ion balance and electrical excitability within cells, as well as in various physiological processes such as nutrient uptake, waste elimination, and signal transduction.

There are several types of cation transport proteins, including:

1. Ion channels: These are specialized protein structures that form a pore or channel through the membrane, allowing ions to pass through rapidly and selectively. They can be either voltage-gated or ligand-gated, meaning they open in response to changes in electrical potential or binding of specific molecules, respectively.

2. Ion pumps: These are active transport proteins that use energy from ATP hydrolysis to move ions against their electrochemical gradient, effectively pumping them from one side of the membrane to the other. Examples include the sodium-potassium pump (Na+/K+-ATPase) and calcium pumps (Ca2+ ATPase).

3. Ion exchangers: These are antiporter proteins that facilitate the exchange of one ion for another across the membrane, maintaining electroneutrality. For example, the sodium-proton exchanger (NHE) moves a proton into the cell in exchange for a sodium ion being moved out.

4. Symporters: These are cotransporter proteins that move two or more ions together in the same direction, often coupled with the transport of a solute molecule. An example is the sodium-glucose cotransporter (SGLT), which facilitates glucose uptake into cells by coupling its movement with that of sodium ions.

Collectively, cation transport proteins help maintain ion homeostasis and contribute to various cellular functions, including electrical signaling, enzyme regulation, and metabolic processes. Dysfunction in these proteins can lead to a range of diseases, such as neurological disorders, cardiovascular disease, and kidney dysfunction.

... are metabolic disorders which lead to impairment in the ability of solutes, such as ... This results in disruptions of renal reabsorption. Examples of these disorders include Iminoglycinuria, renal tubular acidosis ... to be transported across the brush border of the renal tubule. ...
An inborn error of renal tubular transport". The New England Journal of Medicine. 278 (26): 1407-13. doi:10.1056/ ... However, no renal tubular damage or visible deposition of calcium oxalate crystals in kidneys was found in yearling wether ... People with certain rare inborn errors of metabolism have a propensity to accumulate crystal-forming substances in their urine ... The formation of calcium phosphate stones is associated with conditions such as hyperparathyroidism and renal tubular acidosis ...
An inborn error of renal tubular transport". New England Journal of Medicine. 278 (26): 1407-13. doi:10.1056/ ... New defect in renal tubular transport of glycine and imino acids". The American Journal of Medicine. 54 (2): 265-271. doi: ... Iminoglycinuria is an autosomal recessive disorder of renal tubular transport affecting reabsorption of the amino acid glycine ... In mammals, including humans, the transport of amino and imino acids from the lumen (interior) of the intestine or the renal ...
... renal tubular transport, inborn errors MeSH C18.452.648.851.093 - acidosis, renal tubular MeSH C18.452.648.851.191 - ... inborn errors MeSH C18.452.648.798.368 - gout MeSH C18.452.648.798.368.410 - arthritis, gouty MeSH C18.452.648.798.594 - Lesch- ... inborn errors MeSH C18.452.648.066.102 - albinism MeSH C18.452.648.066.102.090 - albinism, ocular MeSH C18.452.648.066.102.100 ... renal tubular MeSH C18.452.076.176.310 - acidosis, respiratory MeSH C18.452.076.176.390 - diabetic ketoacidosis MeSH C18.452. ...
... renal tubular transport, inborn errors MeSH C16.320.565.851.093 - acidosis, renal tubular MeSH C16.320.565.851.191 - ... inborn errors MeSH C16.320.565.798.368 - gout MeSH C16.320.565.798.368.410 - arthritis, gouty MeSH C16.320.565.798.594 - Lesch- ... inborn errors MeSH C16.320.565.066.102 - albinism MeSH C16.320.565.066.102.090 - albinism, ocular MeSH C16.320.565.066.102.100 ... amino acid transport disorders, inborn MeSH C16.320.565.088.400 - Hartnup disease MeSH C16.320.565.088.600 - oculocerebrorenal ...
... renal osteodystrophy MeSH C12.777.419.815 - renal tubular transport, inborn errors MeSH C12.777.419.815.093 - acidosis, renal ... kidney tubular necrosis, acute MeSH C12.777.419.780.500.602 - kidney failure, chronic MeSH C12.777.419.780.625 - renal ... renal artery obstruction MeSH C12.777.419.780 - renal insufficiency MeSH C12.777.419.780.500 - kidney failure MeSH C12.777. ... tubular MeSH C12.777.419.815.191 - aminoaciduria, renal MeSH C12.777.419.815.191.250 - cystinuria MeSH C12.777.419.815.191.457 ...
... (SPCD) is an inborn error of fatty acid transport caused by a defect in the transporter ... The transporter, OCTN2, is located in the apical membrane of the renal tubular cells, where it plays a role in tubular ... Carnitine is needed to transport long chain fatty acids into the mitochondria, where they can be broken down to produce acetyl- ... When carnitine cannot be transported into tissues, fatty acid oxidation is impaired, leading to a variety of symptoms such as ...
When the ECF pH falls (becoming more acidic) the renal tubular cells excrete hydrogen ions into the tubular fluid to leave the ... Almost any homeostatic component can malfunction either as a result of an inherited defect, an inborn error of metabolism, or ... Copper is absorbed, transported, distributed, stored, and excreted in the body according to complex homeostatic processes which ... It is very probable that the renal tubular cells of the distal convoluted tubules are themselves sensitive to the pH of the ...
It may also occur due to a failure of renal tubular transport. Lysine production for animal feed is a major global industry, ... The initial error was caused by the chloroplatinate containing not water in the crystal (as was assumed), but ethanol … ) {{ ... Hoffmann GF, Kölker S (2016). Inborn Metabolic Diseases. Springer, Berlin, Heidelberg. pp. 333-348. doi:10.1007/978-3-662-49771 ... Lysine has also been proposed to be involved in calcium intestinal absorption and renal retention, and thus, may play a role in ...
This will often present as Fanconi syndrome with multiple derangements of renal tubular reabsorption, including tubular ... Inborn errors of carbohydrate metabolism). ... The free glucose molecules can be transported out of the liver ... Renal tubular abnormalities related to hyperlactatemia are seen early in life, likely because prolonged lactic acidosis is more ... When lactate levels are elevated, blood-borne lactic acid competes for the same kidney tubular transport mechanism as urate, ...
Inborn errors of renal tubular transport are metabolic disorders which lead to impairment in the ability of solutes, such as ... This results in disruptions of renal reabsorption. Examples of these disorders include Iminoglycinuria, renal tubular acidosis ... to be transported across the brush border of the renal tubule. ...
Usage: Cystinosis is an autosomal recessive inborn error of metabolism in which the transport of cystine out of lysosomes is ... leading to renal tubular Fanconi Syndrome and progressive glomerular failure, with end stage renal failure by the end of the ... Cystinosis is an autosomal recessive inborn error of metabolism in which the transport of cystine out of lysosomes is abnormal ... In four studies of cystinosis patients before cysteamine was available, renal death (need for transplant or dialysis) occurred ...
Renal Tubular Transport, Inborn Errors [C13.351.968.419.815]. *Renal Aminoacidurias [C13.351.968.419.815.885] ... An autosomal recessive disorder due to defective absorption of NEUTRAL AMINO ACIDS by both the intestine and the PROXIMAL RENAL ... Renal Tubular Transport, Inborn Errors [C12.777.419.815]. *Renal Aminoacidurias [C12.777.419.815.885] ... Renal Tubular Transport, Inborn Errors [C16.320.565.861]. *Renal Aminoacidurias [C16.320.565.861.885] ...
Refractive Errors. *Renal Insufficiency. *Renal Tubular Transport, Inborn Errors. *Reproducibility of Results ...
... has similarities to three X-linked proximal renal tubular disorders that are due to mutations in the renal chloride channel ... of our study expand the spectrum of clinical phenotypes associated with CLCN5 mutations to include this proximal renal tubular ... The annual urinary screening of Japanese children above 3 yr of age has identified a progressive proximal renal tubular ... Renal Tubular Transport, Inborn Errors, Sequence Analysis, DNA, Sex, Xenopus ...
Purine-Pyrimidine Metabolism, Inborn Errors. *Renal Tubular Transport, Inborn Errors. *Steroid Metabolism, Inborn Errors ... Inborn errors of metabolism characterized by defects in specific lysosomal hydrolases and resulting in intracellular ...
Pediatric Endocrinology and Inborn Errors of Metabolism. New York, NY: McGraw Hill; 2009. 619-64. ... Prié D, Friedlander G. Genetic disorders of renal phosphate transport. N Engl J Med. 2010 Jun 24. 362(25):2399-409. [QxMD ... Renal Tubular Phosphate Reabsorption. The renal tubular reabsorption of phosphate (TRP) is calculated with the following ...
Renal Tubular Transport, Inborn Errors [C16.320.831] Renal Tubular Transport, Inborn Errors ...
Renal Tubular Transport, Inborn Errors [C16.320.831] * Skin Diseases, Genetic [C16.320.850] ...
Purine-Pyrimidine Metabolism, Inborn Errors. *Renal Tubular Transport, Inborn Errors. *Steroid Metabolism, Inborn Errors ... Inborn Errors" by people in this website by year, and whether "Lipid Metabolism, Inborn Errors" was a major or minor topic of ... "Lipid Metabolism, Inborn Errors" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH ( ... Errors in the metabolism of LIPIDS resulting from inborn genetic MUTATIONS that are heritable. ...
Wilson disease is an inborn error of copper metabolism that may present with neurologic, hepatic, or psychiatric symptoms. It ... Hemolytic anemia and renal tubular acidosis also may occur.. Diagnosis. Determining hepatic copper content via liver biopsy is ... The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993 Dec. 5(4): ... which encodes a copper transporting P-type adenosine triphosphatase that is expressed in the liver and kidney. [16] Excess ...
Kidney Tubular Necrosis, Acute Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Inborn Error use Renal Tubular Transport, Inborn Errors Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, ... Kidney Tubular Necrosis, Acute Kidney Tubular Transport, ... Kidney Failure use Renal Insufficiency Kidney Failure, Acute ...
Kidney Tubular Necrosis, Acute. Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Kidney Tubular Necrosis, Acute Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Kidney Tubular Necrosis, Acute Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Inborn Error use Renal Tubular Transport, Inborn Errors Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, ... Kidney Tubular Necrosis, Acute Kidney Tubular Transport, ... Kidney Failure use Renal Insufficiency Kidney Failure, Acute ...
Kidney Tubular Necrosis, Acute Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Kidney Tubular Necrosis, Acute Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Inborn Error use Renal Tubular Transport, Inborn Errors Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, ... Kidney Tubular Necrosis, Acute Kidney Tubular Transport, ... Kidney Failure use Renal Insufficiency Kidney Failure, Acute ...
Kidney Tubular Necrosis, Acute Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Kidney Tubular Necrosis, Acute Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Kidney Tubular Necrosis, Acute Kidney Tubular Transport, Inborn Errors use Renal Tubular Transport, Inborn Errors ...
Purine-Pyrimidine Metabolism, Inborn Errors [C16.320.565.798] * Renal Tubular Transport, Inborn Errors [C16.320.565.893] ... Genetic Diseases, Inborn [C16.320] * Metabolism, Inborn Errors [C16.320.565] * Amino Acid Metabolism, Inborn Errors [C16.320. ... AA TRANSPORT DIS INBORN. Entry Term(s). Inborn Transport Disorders, Amino Acid Inherited Amino Acid Transport Disorders ... Amino Acid Metabolism, Inborn Errors [C18.452.648.100] * Amino Acid Transport Disorders, Inborn [C18.452.648.151] * Hartnup ...
Purine-Pyrimidine Metabolism, Inborn Errors. *Renal Tubular Transport, Inborn Errors. *Steroid Metabolism, Inborn Errors ... A disease that results from a congenital defect in ELECTRON TRANSPORT COMPLEX IV. Defects in ELECTRON TRANSPORT COMPLEX IV can ... ELECTRON TRANSPORT COMPLEX IV deficiency caused by mutation in SURF1 manifests itself as LEIGH DISEASE; that caused by mutation ...
Purine-Pyrimidine Metabolism, Inborn Errors [C16.320.565.798] * Renal Tubular Transport, Inborn Errors [C16.320.565.893] ... METAB INBORN ERR. Entry Term(s). Inborn Errors of Metabolism Metabolism Errors, Inborn Public MeSH Note. 65. History Note. 65. ... Metabolism, Inborn Errors [C16.320.565] * Amino Acid Metabolism, Inborn Errors [C16.320.565.100] ... Metabolism, Inborn Errors [C18.452.648] * Amino Acid Metabolism, Inborn Errors [C18.452.648.100] ...
Inborn Errors of Metabolism (Storage Disease). This is a group of genetic disease with lack of or dysfunction of a key enzyme ... decreased urinary excretion of hydrogen ion and reduced renal tubular reabsorption of bicarbonate. Renal secondary ... Insulin deficiency results in failure of glucose transport into muscle and adipose tissue. Clinical signs including exercise ... Sequelae to hypercalcaemia include chronic renal failure, tubular cell toxicity and reduced excitability of smooth muscle, ...
Renal Artery Obstruction. *Renal Insufficiency. *Renal Nutcracker Syndrome. *Renal Tubular Transport, Inborn Errors ... Death of cells in the KIDNEY CORTEX, a common final result of various renal injuries including HYPOXIA; ISCHEMIA; and drug ...
Purine-Pyrimidine Metabolism, Inborn Errors. *Renal Tubular Transport, Inborn Errors. *Steroid Metabolism, Inborn Errors ... Inborn" by people in this website by year, and whether "Amino Acid Transport Disorders, Inborn" was a major or minor topic of ... "Amino Acid Transport Disorders, Inborn" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, ... Below are the most recent publications written about "Amino Acid Transport Disorders, Inborn" by people in Profiles. ...
Research progress on renal calculus associate with inborn error of metabolism. / é ä¼ æ §ä»£è°¢ç¼ºé ·æ è ´è ¾ç» ç ³ç ç©¶è¿ å ... Erros Inatos do Transporte Tubular Renal/genética , Erros Inatos do Transporte Tubular Renal/terapia , Esquizofrenia/genética ... Gene mutations cause changes in enzyme function, metabolic pathway, ion transport, and receptor sensitivity, causing defects in ... Erros Inatos do Transporte Tubular Renal/induzido quimicamente , Erros Inatos do Transporte Tubular Renal/genética , Erros ...
  • Inborn errors of metabolism characterized by defects in specific lysosomal hydrolases and resulting in intracellular accumulation of unmetabolized substrates. (umassmed.edu)
  • Lipid Metabolism, Inborn Errors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (musc.edu)
  • Errors in the metabolism of LIPIDS resulting from inborn genetic MUTATIONS that are heritable. (musc.edu)
  • This graph shows the total number of publications written about "Lipid Metabolism, Inborn Errors" by people in this website by year, and whether "Lipid Metabolism, Inborn Errors" was a major or minor topic of these publications. (musc.edu)
  • Below are the most recent publications written about "Lipid Metabolism, Inborn Errors" by people in Profiles. (musc.edu)
  • Gene mutations cause changes in enzyme function, metabolic pathway, ion transport, and receptor sensitivity, causing defects in oxalic acid metabolism, cystine metabolism, calcium ion metabolism, or purine metabolism, which may lead to the formation of renal calculus. (bvsalud.org)
  • This article reviews the research progress on renal calculus associated with inborn error of metabolism, to provide reference for early screening, diagnosis, treatment, prevention and recurrence of renal calculus. (bvsalud.org)
  • Evaluating patients with possible inborn errors of metabolism using random urine specimens. (marshfieldlabs.org)
  • Many inborn errors of amino acid metabolism that affect amino acid transport or metabolism have been identified, such as phenylketonuria and tyrosinemia. (marshfieldlabs.org)
  • Carbohydrate metabolism, inborn errors refer to genetic disorders that affect the body's ability to properly process carbohydrates, leading to various metabolic disorders. (lookformedical.com)
  • Approach to the Patient With a Suspected Inherited Disorder of Metabolism Most inherited disorders of metabolism (inborn errors of metabolism) are rare, and therefore their diagnosis requires a high index of suspicion. (msdmanuals.com)
  • Initial testing Most inherited disorders of metabolism (inborn errors of metabolism) are rare, and therefore their diagnosis requires a high index of suspicion. (msdmanuals.com)
  • Inborn errors of renal tubular transport are metabolic disorders which lead to impairment in the ability of solutes, such as salts or amino acids, to be transported across the brush border of the renal tubule. (wikipedia.org)
  • Examples of these disorders include Iminoglycinuria, renal tubular acidosis and Gitelman syndrome. (wikipedia.org)
  • The disorder, which has a familial predisposition and occurs predominantly in males, has similarities to three X-linked proximal renal tubular disorders that are due to mutations in the renal chloride channel gene, CLCN5. (ox.ac.uk)
  • Prié D, Friedlander G. Genetic disorders of renal phosphate transport. (medscape.com)
  • Disorders characterized by defective transport of amino acids across cell membranes. (nih.gov)
  • General elevations in urine amino acid levels, called aminoaciduria, can be seen in disorders with amino acid transport defects such as lysinuric protein intolerance and Hartnup disease, as well as in conditions with renal tubular dysfunction including Lowe syndrome and Dent disease. (marshfieldlabs.org)
  • Glomerulonephropathies and Disorders of Tubular Function 92. (booksca.ca)
  • Sly, W. S., Sato, S. & Zhu, X. L. Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis. (diabetestalk.net)
  • In secondary carnitine deficiency, which is caused by other metabolic disorders (eg, fatty acid oxidation disorders, organic acidemias), carnitine depletion may be secondary to the formation of acylcarnitine adducts and the inhibition of carnitine transport in renal cells by acylcarnitines. (medscape.com)
  • Metabolic acidosis develops because of impaired renal tubular ammonia production, decreased urinary excretion of hydrogen ion and reduced renal tubular reabsorption of bicarbonate. (vin.com)
  • This results in disruptions of renal reabsorption. (wikipedia.org)
  • Valproic acid may cause an acquired type of secondary carnitine deficiency by directly impairing renal tubular reabsorption of carnitine. (medscape.com)
  • Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero. (nih.gov)
  • Recent studies have revealed that gene mutations may lead to metabolic defects which are associated with the formation of renal calculus, and single gene mutation is involved in relative high proportion of renal calculus. (bvsalud.org)
  • An autosomal recessive disorder due to defective absorption of NEUTRAL AMINO ACIDS by both the intestine and the PROXIMAL RENAL TUBULES. (uchicago.edu)
  • The annual urinary screening of Japanese children above 3 yr of age has identified a progressive proximal renal tubular disorder characterized by low molecular weight proteinuria, hypercalciuria, and nephrocalcinosis. (ox.ac.uk)
  • Thus, the results of our study expand the spectrum of clinical phenotypes associated with CLCN5 mutations to include this proximal renal tubular disorder of Japanese children. (ox.ac.uk)
  • Idiopathic low molecular weight proteinuria associated with hypercalciuric nephrocalcinosis in Japanese children is due to mutations of the renal chloride channel (CLCN5). (ox.ac.uk)
  • In the absence of treatment, renal disease progresses from microscopic hematuria (microhematuria) to proteinuria, progressive renal insufficiency, and end-stage renal disease (ESRD) in all males with XLAS, and in all males and females with ARAS. (nih.gov)
  • Defects in ELECTRON TRANSPORT COMPLEX IV can be caused by mutations in the SURF1, SCO2, COX10, or SCO1 genes. (uams.edu)
  • AIM: Biallelic loss-of-function FAM20A mutations cause amelogenesis imperfecta (AI) type IG, better known as enamel renal syndrome (ERS), characterized by severe enamel hypoplasia, delayed/failed tooth eruption, intrapulpal calcifications, gingival hyperplasia and nephrocalcinosis. (bvsalud.org)
  • Assadi F. Lack of NPHP2 mutations in a newborn infant with Joubert syndrome-related disorder presenting as end-stage renal disease. (rush.edu)
  • SLC22A5 mutations can affect carnitine transport by impairing maturation of transporters to the plasma membrane. (medscape.com)
  • Boron, W. F. Acid base transport by the renal proximal tubule. (diabetestalk.net)
  • Defects of amino acid transport in the renal tubule include cystinuria and Hartnup disease, which are discussed elsewhere. (msdmanuals.com)
  • 60% of genetic aHUS progresses to end-stage renal disease (ESRD). (nih.gov)
  • In Alport syndrome (AS) a spectrum of phenotypes ranging from progressive renal disease with extrarenal abnormalities to isolated hematuria with a non-progressive or very slowly progressive course is observed. (nih.gov)
  • Renal calculus is a common disease with complex etiology and high recurrence rate. (bvsalud.org)
  • Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. (nih.gov)
  • Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. (nih.gov)
  • A disease that results from a congenital defect in ELECTRON TRANSPORT COMPLEX IV. (uams.edu)
  • Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. (rush.edu)
  • [ 5 , 6 ] However, lowered serum phosphate levels correlated with an equal degree of renal tubular reduction of tubular time of maximal concentration (T max ) of phosphate in both sexes, pointing to an additional factor in the creation of the bone disease in affected males. (medscape.com)
  • Clinical Evaluation of Renal and Urinary Tract Disease 90. (booksca.ca)
  • Preterm newborns also may be at risk for developing carnitine deficiency because immature renal tubular function combined with impaired carnitine biosynthesis renders them strictly dependent on exogenous supplies to maintain normal plasma carnitine levels. (medscape.com)
  • Renal secondary hyperparathyroidism results from phosphorus retention and decreased production of calcitriol. (vin.com)
  • Terminal stages of renal failure may present in seizures and tetany. (vin.com)
  • Amyloidosis, which can lead to renal failure, is the most severe complication, if untreated. (nih.gov)
  • Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. (nih.gov)
  • Maintaining Appropriate Fluid Quantity Stabilize Persevere in precise intake and achievement monitoring and recording to evaluate the advancement toward renal failure. (mein-schoenefeld.info)
  • It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention. (rush.edu)
  • We explored whether LPL affects (a) lipoprotein transport across bovine aortic endothelial cells or (b) lipoprotein binding to subendothelial cell matrix (retention). (jci.org)
  • In intestinal ENTEROCYTES it mediates intracellular calcium transport from apical to basolateral membranes via calcium binding at two EF-HAND MOTIFS. (lookformedical.com)
  • and transport across the membranes of intracellular organelles. (nih.gov)
  • Calcium-binding proteins that are found in DISTAL KIDNEY TUBULES, INTESTINES, BRAIN, and other tissues where they bind, buffer and transport cytoplasmic calcium. (lookformedical.com)
  • They can act as transport proteins, regulator proteins, or activator proteins. (lookformedical.com)
  • Dr. Tan is Assistant Professor of Medicine, Division of Renal-Electrolyte, Department of Medicine at the University of Pittsburgh. (regenerativemedicine.net)
  • Reducing equivalents produced in the Krebs cycle and in the beta-oxidation spirals are passed along a series of protein complexes embedded in the inner mitochondrial membrane (the electron transport chain). (medlink.com)
  • The electron transport chain consists of 4 multimeric complexes (I to IV) plus 2 small electron carriers, coenzyme Q10 (or ubiquinone) and cytochrome c . (medlink.com)
  • It plays a central role in the transport of IRON throughout the circulation. (lookformedical.com)
  • Radiographs demonstrate thin flattened vertebrae, short ribs, small sacrosciatic notch, extremely short long tubular bones, and markedly short and curved femora (telephone receiver-like appearance). (medscape.com)